Supplemental Material

New Exposure Biomarkers as Tools For Breast Cancer
Epidemiology, Biomonitoring, and Prevention: A Systematic Approach Based on Animal Evidence

Ruthann A. Rudel, Janet M. Ackerman, Kathleen R. Attfield, and Julia Green Brody

Table of Contents

<table>
<thead>
<tr>
<th>Table of Contents</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table S1. Summary of exposure sources and biomonitoring methods for 102 rodent mammary gland carcinogens with likely human exposure</td>
<td>2</td>
</tr>
<tr>
<td>Table S2. Guide to breast cancer cohort studies (studies assessing breast cancer incidence, recurrence, or survival)</td>
<td>25</td>
</tr>
<tr>
<td>Table S3. Guide to breast cancer cohort studies (studies assessing pubertal development)</td>
<td>33</td>
</tr>
<tr>
<td>References</td>
<td>36</td>
</tr>
</tbody>
</table>
Table S1. Summary of exposure sources and biomonitoring methods for 102 rodent mammary gland carcinogens with likely human exposure.

These 102 were selected from the 216 rodent mammary gland carcinogens compiled by Rudel et al. (2007) based on likelihood of general population or occupational exposure, because they are produced in high volumes, over 5000 women are exposed occupationally each year, because they are present in food, air position, or consumer products, or were identified as exposure pharmaceuticals by Friedman et al. (2009).

<table>
<thead>
<tr>
<th>CAS</th>
<th>Name</th>
<th>Chemical group</th>
<th>Exposure summary</th>
<th>Biomarker summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>106-99-0</td>
<td>1,3-Butadiene</td>
<td>1,3-Butadiene</td>
<td>The primary route of exposure is inhalation from gasoline fumes, automobile exhaust, and cigarette smoke. Over 12 billion pounds/year are produced globally, and occupational exposure occurs in many industries, especially synthetic rubber manufacturing and petroleum refining (OSHA 2012). Although some food packaging contains residual 1,3-butadiene, the available data indicate that it does not usually migrate to the food. Certain cooking oils, such as rapeseed oil (canola) release 1,3-butadiene when heated (NTP 2011). It is on the Canadian Priority Substances List, with exposures from urban ambient air and cigarette smoke (Health Canada 2000). It is listed as a Proposition 65 carcinogen and developmental toxicant (California OEHHA 2014). Many occupational studies, epidemiological studies, and studies comparing smokers and non-smokers have measured biomarkers of exposure to 1,3-butadiene (BD) in blood and urine, and a few have measured biomarkers in exhaled breath. Widely used approaches include the measurement of DNA and hemoglobin adducts in blood (Ifyasyova et al. 2009; Ogawa et al. 2006; Vacek et al. 2010), and the measurement of mercapturic acids in urine. One is planning to add UPLC-ES-MS/MS testing for the BD-derived mercapturic acids N-acetyl-S-(3,4-dihydroxybutyl)-L-cysteine (DHBMA; LOD 0.7 ng/mL), N-acetyl-S-(1-hydroxymethyl-2-propanyl)-L-cysteine (MHBMA1; LOD 0.7 ng/mL), N-acetyl-S(2-hydroxy-3-butenyl)-L-cysteine (MHBMA2; LOD 0.7 ng/mL), and N-acetyl-S-(4-hydroxy-2-buten-1-yl)-L-cysteine (MHBMA3; LOD 0.6 ng/mL) to future NHANES reports (Alwis et al. 2012). A CDC pilot study found that DHBMA and MHBMA2 levels were different in smokers and non-smokers, while MHBMA1 was not detectable in the majority of both smokers and non-smokers, and MHBMA2 was detectable in the majority of smokers but not non-smokers (Alwis et al. 2012). DNA and hemoglobin adducts of epoxide metabolites of 1,3-BD have been measured in blood (Ifyasyova et al. 2009; Svenberg et al. 2011; Zhao et al. 2001), N-(2,3,4-trihydroxybutyl)lysine (THBHL) is the most prevalent Hb adduct in humans. Many studies have also measured N-(2-hydroxy-3-butenyl)lysine (HBVL). The hemoglobin adduct N,N-(2,3-dihydroxy-1,4-butan-1-yl)lysine (pyr-val) reflects exposure to 1,2,3,4-tetrahydroxylethane (TDEE), the most toxic epoxide metabolite of 1,3-butadiene, and methods to detect it in general population samples have only recently been developed (Boyden et al. 2012; Ifyasyova et al. 2009). Older studies have measured adducts via Edman method GC-MS or MS/MS, but newer studies tend to use trypsin hydrolysis, immunolaffinity purification, and LC-MS/MS (Ogawa et al. 2006; Svenberg et al. 2011). A few studies have shown lower levels of Hb adducts, but generally similar levels of genetic damage, in women compared to men after exposures to similar amounts of BD (Albertini et al. 2007; Vacek et al. 2010). Mercapturic acids, measured by various forms of LC-MS/M (Eckert et al. 2010; Kopata et al. 2011; Sakpota et al. 2006; Schettgen et al. 2009), are the most commonly used urinary biomarkers of BD, though Shen et al. (2009) describe a method for measurement of the diol metabolite 3-buten-1,2-diol. Kotarblj et al. (2011) measured trihydroxybutyl mercapturic acid in urine from smokers and non-smokers by HPLC-ESI-MS/MS, finding higher levels in smokers but detecting it in non-smokers as well. Eckert et al. (2011) detected dihydroxybutyl mercapturic acid (DHBMA) in all urine samples from non-occupationally exposed Germans and monohydroxybutenyl mercapturic acids (MHBMA; comprising MHBMA1, MHBMA2, and MHBMA3) in 10%, and did not find a difference in median levels between smokers and non-smokers. Carmella et al. (2009) measured MHBMA and DHBMA, along with urinary metabolites of other PARs, in subjects who had recently stopped smoking, finding that all metabolites but DHBMA had declined significantly by three days after cessation of smoking. Arayasiri et al. (2010) found no difference in MHBMA levels between traffic policemen and office policemen in central Bangkok, and Hecht et al. (2010) found no significant differences in levels of mercapturic acid biomarkers of 1,3-butadiene between non-smoking Chinese women who cooked at home and those who did not. Sakpota et al. (2006) found MHBMA and DHBMA elevated, but nonsignificantly, in urine from toll collectors compared to other subjects, and in urine collected from people in the city on a weekday compared to urine collected from people in suburbs on weekends. Perbellini et al. (2003b) found significantly higher levels of BD in exhaled breath (LOD 0.8 ng/L), blood (LOD 0.8 ng/L), and urine (LOD 1 ng/L) from smokers than from non-smokers. Gordon et al. (2002) also measured BD in exhaled breath of smokers and non-smokers, and Smith et al. (2008) measured BD in exhaled breath during and after 20 minutes of intentional inhalation exposure. Many studies are reviewed by Wiang et al. (2011), Svenberg et al. (2011), Ifyasyova et al. (2009), Ogawa et al. (2006), Albertini et al. (2003), and Boogaard et al. (2002).</td>
<td></td>
</tr>
<tr>
<td>79-06-1</td>
<td>Acrylamide</td>
<td>Acrylamide</td>
<td>The general public may be exposed through consumption of certain foods (e.g. french fries). Acrylamide is formed during heating of starch-rich foods to high temperatures. Other sources of exposure could include drinking water contaminated with polycyclicamide-formic acids used in water treatment and contact with polycyclicamide-containing consumer products. Tobacco smoke is a substantial non-food source of exposure to acrylamide (NLM 2011). It is used in the manufacture of consumer products, including textiles, contact lenses, building materials, cosmetic and soap preparations, water-based paints, home appliances, automobile parts, food packaging adhesives, paper, gelatin capsules, and in home-use adhesives and caucks (NLM 2013). It is an environmental contaminant (NTP 2011). It is listed as a Proposition 65 carcinogen (California OEHHA 2014). It is on the REACH SVHC Candidate List, with exposures from drinking water, cosmetics, and soil conditioners for the garden (ECHA 2013). Many studies have been found to be higher in exposed workers and in smokers (Alwis et al. 2012; Huang et al. 2011a; Huang et al. 2011b; CM Li et al. 2005). At least one study has measured acrylamide in breast milk and placenta (Sörgel et al. 2002). Additional studies using biomarkers of acrylamide exposure are reviewed in Ifyasyova et al. (2009), Dybing et al. (2005), Knudsen et al. (2007), and Ogawa et al. (2006).</td>
<td></td>
</tr>
<tr>
<td>CAS</td>
<td>Name</td>
<td>Chemical group</td>
<td>Exposure summary</td>
<td>Biomarker summary</td>
</tr>
<tr>
<td>---------</td>
<td>-----------------------------</td>
<td>------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>39156-41-7</td>
<td>2,4-Diaminocisole sulfate</td>
<td>Aromatic amine</td>
<td>2,4-diaminocisole sulfate is an aromatic amine which was used extensively in hair dyes and in the dyeing of furs until the late 1970s (IARC 2001a; NTP 2011). The maximum concentration of the compound in hair-dye preparations was approximately 1.5% (NTP 2011). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).</td>
<td>No studies were found using biomarkers to measure exposure to 2,4-diaminocisole sulfate.</td>
</tr>
<tr>
<td>95-80-7</td>
<td>2,4-Diaminotoluene</td>
<td>Aromatic amine</td>
<td>TDA is a metabolite of toluene disocyanate (TDI), and exposure can occur from use of products containing uncured TDI and its related polyisocyanates, such as spray-applied sealants and coatings, or wheels and axles such products are used in or around buildings including homes or schools. Potential consumer exposure may occur as a result of the presence of trace contaminants in products that contain TDA-based dyes, such as furs, leather, silk, textiles, and wool, and a number of hair dyes contained this chemical prior to the 1970s. TDA is used in the production of polyurethane foam and sealants, and it has been identified as a degradation product of polyester urethane foam used to cover silicone breast implants. Relatively high levels were detected in plasma and urine of patients one month after surgery, and measurable levels were detected in patients up to two years after surgery. Small amounts of TDA are released from boil-in bags upon prolonged boiling (NTP 2011). It is listed as a Proposition 65 carcinogen (California OEHHA 2014). It is listed on the REACH SVHC Candidate List, with exposures from TDI production and explosives manufacturing (ECHA 2013). TDI is a US EPA Action Plan Chemical, with occupational exposures and exposures from consumer products, such as sealants used in building materials (US EPA 2013a).</td>
<td>Many studies have investigated 2,4-diaminotoluene levels in blood and urine of occupationally exposed workers, as well as nonexposed control subjects and women with breast implants containing polyurethane. 2,4-diaminotoluene (also known as 2,4-toluene diamine or 2,4-TDA) is a metabolite and degradation product of 2,4-toluene disocyanate (2,4-TDI), and is often used as a biomarker of exposure to 2,4-TDI. Hester et al. (1997) used GC-MS, with LLOQ 10 µg/ml on urine and serum samples from 61 patients with breast implants and 21 women without. This study found no detectable 2,4-TDA in serum of either group. Of the women with breast implants, 30 had quantifiable levels of 2,4-TDA in their urine, and 18 had detectable but not quantifiable levels. Of the controls, 7 had detectable levels in urine but none had quantifiable levels. Dalene et al. (1990) used GC-MS to measure 2,4-TDA in blood and urine from 15 factory workers exposed to TDI-based foam, also taking samples from 4 of the workers during an exposure-free period. Plasma levels ranged from below 0.1 to 5.5 nmol/l, and variation was greater between workers than between samples from any given worker. Senbro et al. (2004) measured plasma, urine, and air for 81 exposed workers and 121 unexposed workers, finding strong associations between the levels in both media and results of personal air sampling. Jones et al. (2005) measured hemoglobin adducts in Chinese workers exposed to nitrotoluenes, finding 4-amino-2-nitrotoluene 24 times more abundant than 2,4-TDA in workers exposed to 2,4-TDI. Rosenberg et al. (2002) used GC-MS with LLOQ 0.25 nmol/l on urine from workers in 5 polyurethane-processing environments. The highest measured TDA concentration (including 2,4- and 2,6-TDA) was 0.79 nmol/mmol creatinine, while the mean in unexposed workers was 0.08 nmol/mmol creatinine. Maitre et al. (1993) found urinary TDA concentrations ranging from 6.8 to 31.7 µg/g creatinine in postshift samples from 9 workers in TDI-based polyurethane production. These concentrations were linearly related to atmospheric concentrations of TDI. See also methods for TDI.</td>
</tr>
<tr>
<td>613-13-8</td>
<td>2-Aminanthracene</td>
<td>Aromatic amine</td>
<td>2-aminanthracene is formed from the incomplete combustion of organic materials, is a constituent of synthetic fuel, and is a research chemical (NLM 2011).</td>
<td>No studies were found using biomarkers of exposure to 2-aminanthracene.</td>
</tr>
<tr>
<td>81-94-1</td>
<td>3,3'-Dichlorobenzidine</td>
<td>Aromatic amine</td>
<td>For the general population the chance of exposure to 3,3'-dichlorobenzidine (DCB) and its dichloride salt is probably insignificant; the greatest chance of exposure is from the improper land disposal of DCB. In the past, exposure may have occurred during the use of pressurized spray containers of paints, lacquers, and enamels containing traces of benzidine yellow, an azo dye derived from DCB. The use of DCB to synthesize dyes ended in 1986, although it is still used to produce pigments (NTP 2011). It is on the Canadian Priority Substances List, with occupational exposures from production of pigments for printing inks, textiles, paints, plastics and crayons (Health Canada 2007b). It is listed as a Proposition 65 carcinogen (California OEHHA 2014). It is an EPA Action Plan Chemical, under the class of benzidine dyes (CDC 2012a).</td>
<td>Multiple studies have measured 3,3'-dichlorobenzidine (DCB) in the urine of occupationally exposed humans, and one study has developed a method to measure it in the blood of rats. Guebert et al. (2007) used GC-MS on urine, detecting DCB levels of 1.62-8.9 ppb in 4 of 47 samples taken from workers in a chemical plant either after a one-month vacation or after 4 months of regular work. Hatfield et al. (1982), using GC-MS with LOD 0.2 ppb, did not detect DCB or monoacetyl-DCB in urine samples from 36 exposed workers or from 12 controls, although a nonspecific colorimetric test for aromatic amines, with LOD 1 ppb, was positive for 6 of the exposed workers and 1 of the controls. Lee and Shin (2002) developed GC-MS-SIM, with LOD 0.5 µg/L for DNA adducts and 1 ng/g hemoglobin for hemoglobin adducts in donors.</td>
</tr>
<tr>
<td>CAS</td>
<td>Name</td>
<td>Chemical group</td>
<td>Exposure summary</td>
<td>Biomarker summary</td>
</tr>
<tr>
<td>-------</td>
<td>----------------------------------------------</td>
<td>-------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>119-90-4</td>
<td>3,3’-Dimethoxybenzidine (o-dianisidine)</td>
<td>Aromatic amine</td>
<td>Exposure could occur from trace contaminants in products that are made with 3,3’-dimethoxybenzidine. It is used as a dye for paper, plastics, rubber, and textiles (NTF 2011). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).</td>
<td>A few relatively old studies have measured 3,3’-dimethoxybenzidine in human urine, and a few have investigated other methods to measure biomarkers of exposure. Lowry et al. (1980) used a colorimetric screening method to detect trace 3,3’-dimethoxybenzidine in urine from occupationally exposed workers. Bowman et al. (1976) used a spectrophotofluorometric method to measure 3,3’-dimethoxybenzidine in human urine and rat blood. Birner et al. (1990) measured hemoglobin adducts in rats, and Rodgers et al. (1983) measured 3,3’-dimethoxybenzidine and a few metabolites in rat urine. Methods for measuring exposure to benzidine might be adaptable to measure exposure to 3,3’-dimethoxybenzidine.</td>
</tr>
<tr>
<td>119-93-7</td>
<td>3,3’-Dimethylbenzidine</td>
<td>Aromatic amine</td>
<td>Swimming pool water test kits contain 0.5% to 1.0% 3,3’-dimethylybenzidine. Exposure may occur if the test solutions are emptied into the pool. Residual levels of 3,3’-dimethylbenzidine may be present in dimethylbenzidine-based dyes and pigments and in the final consumer products (IARC 1993c; NTP 2005).</td>
<td>A few relatively old studies have measured 3,3’-dimethylbenzidine in human urine, and a few have investigated other methods to measure biomarkers of exposure. Lowry et al. (1980) used the colorimetric screening method to detect trace 3,3’-dimethylbenzidine in urine from occupationally exposed workers. Bowman et al. (1976) used a spectrophotofluorometric method to measure 3,3’-dimethylbenzidine in human urine and rat blood. Birner et al. (1990) measured hemoglobin adducts in rats, and Rodgers et al. (1983) measured 3,3’-dimethylbenzidine and a few metabolites in rat urine. Methods for measuring exposure to benzidine might be adaptable to measure exposure to 3,3’-dimethylbenzidine.</td>
</tr>
<tr>
<td>101-14-4</td>
<td>4,4’-Methylene-bis(2-chloroaniline)</td>
<td>Aromatic amine</td>
<td>The general population can be exposed to MOCA in contaminated areas or upon consumption of certain types of plants grown in MOCA-contaminated soil (IARC 1993c). It is used as a curing agent for roofing and wood sealing in Japan and Asia (IARC 1993c). CPSC reported that residual levels may be present in final products such as polurethane foam and other plastic components. However, data describing actual levels of impurities and the potential for consumer exposure are lacking (IARC 1993c; NTP 2005). It is a TSCA Work Plan Chemical, identified as low likelihood of exposure. Relatively small releases to the environment have been reported (US EPA 2012). It is listed as a Proposition 65 carcinogen (California OEHHA 2014). It is on the REACH SVHC Candidate List, with occupational exposure from dermal contact, and little information about consumer exposure (ECHA 2013).</td>
<td>A few studies have measured MOCA or its metabolites in the urine of occupationally exposed subjects, and methods have been developed to measure exposure to MOCA in blood. NIOSH uses GC-ECD (NIOSH 1994b), to measure MOCA in urine with LOD 1 µL/L and LOQ 10 µg/L given initial samples of 50 to 100 mL. Among others, Cocker et al. (2009), Keen et al. 2011 (2011), Shih et al. (2007), and Murray and Edwards (1999) measured MOCA and a few metabolites in the urine of exposed workers, with detection frequencies varying between studies from 51% to 100%. Shih et al. (2007), using SPE-LC-MS/MS, reports LODs for MOCA and a metabolite at ~200-400x below mean levels in urine from exposed workers, and ~40-60x below medians. Murray and Edwards (1999) detected MOCA in the urine of each of 12 exposed workers, and not in the urine of 18 control subjects. Keen et al. (2011) found no correlation between sycanates and MOCA in urine. Vaughn and Kenyon (1996) developed a GC-MS method to test MOCA and its protein adducts and conjugates in blood, with LOD &quot;well below the levels found for occupationally exposed individuals&quot;, and detected MOCA in the blood of all 5 exposed workers tested.</td>
</tr>
<tr>
<td>92-67-1</td>
<td>4-Aminobiphenyl</td>
<td>Aromatic amine</td>
<td>The potential for exposure to 4-aminoaniphenyl is low because it has no current commercial uses. It formerly was used as a rubber antioxidant, as a dye intermediate, and in the drug and cosmetic color additive D&amp;C yellow no. 1, which was discontinued in the 1970s. Mainstream cigarette smoke was reported to contain 4-aminoaniphenyl at levels of 2.4 to 4.6 ng per cigarette (unfiltered) and 0.2 to 23 ng per cigarette (filtered), and sidestream smoke to contain up to 140 ng per cigarette (NTP 2011). It is listed as a Proposition 65 carcinogen (California OEHHA 2014). It is on the REACH SVHC Candidate List (ECHA 2013).</td>
<td>Many general population and occupational studies have used biomarkers of exposure to 4-aminobiphenyl (4-ABP) in blood and urine. Breast, bladder, tissue and saliva have also been used. The most common biomarkers are adducts of 4-ABP and hemoglobin (4-ABP-Hb) measured in blood, and 4-ABP measured in urine. Many studies, using either GC-MS (often with NCI) or HPLC-MS/MS, have found higher levels of 4-ABP-Hb in smokers than in non-smokers, and higher levels among heavier smokers compared to lighter smokers (Dallinga et al. 1998; Hammond et al. 1993; Mendes et al. 2009; Myers et al. 1996; Roethig et al. 2009; Sarkar et al. 2006; Seyler and Bernert 2011). 4-ABP-Hb levels tend to be higher in maternal blood than in corresponding cord blood samples (Myers et al. 1996), and among smokers they were higher in older people compared to younger, males compared to females, and white people compared to black people (Mendes et al. 2009). Peluso et al. (2008) found small but significant inverse relationships between fiber intake, fruit intake, and BMI and 4-ABP-Hb levels. Others have investigated associations between 4-ABP-Hb and bladder cancer or other diseases, often finding higher adduct levels in cases than in controls (Airoldi et al. 2005; Del Santo et al. 1991; Skipper et al. 2003). Richter et al. (2001) found higher levels of 4-ABP-Hb in children living in bigger cities than those in smaller cities. A study in dye factories in India found much higher levels of 4-ABP-Hb in workers exposed to benzene as opposed to those exposed to dyes (Beyerbach et al. 2008), while a study in rubber factories found no difference between exposed and unexposed workers (Ward et al. 1996). Multiple studies, mostly using GC-MS, have found higher levels of 4-ABP in the urine of smokers compared to non-smokers (Riedel et al. 2006; Seyler and Bernert 2011), although at least one study (Grimmer et al. 2000) found no such difference. A recent meta-analysis (Van Hemelrijck et al. 2009) found an association between urinary or blood 4-ABP and secondhand smoke exposure but not bladder cancer. Schettgen et al. (2010) couldn’t detect 4-ABP in urine of two subjects after they had applied hair dye, but Ambroseone et al. (2007) found ABP-DNA adducts in epithelial cell DNA isolated from human breast milk in women using hair dyes. Bessette et al. (2010) used LC-ESI/MS/MS to measure 4-ABP-derived DNA adducts in saliva, but adducts were only detectable in the saliva of two smokers out of 37 volunteers. Zayas et al. (2007) used LC-MS/MS to measure DNA adducts in bladder tissue from 27 bladder cancer patients, detecting DNA adducts in samples from 12. Zayas et al. (2007) found no correlation between levels of 4-ABP-Hb and DNA adducts in bladder tissue. Gu et al. (2012) attempted to measure 4-ABP-derived DNA adducts in 70 tumor-adjacent mammary tissue samples, but did not detect any. Birner et al. (1990) found that 4-ABP-Hb adducts are formed in benzidine-treated rats.</td>
</tr>
<tr>
<td>99-59-2</td>
<td>5-Nitro-ortho-anisidine</td>
<td>Aromatic amine</td>
<td>5-nitro-ortho-anisidine is used as a chemical intermediate in the production of C.I. Pigment Red 23 which is used as a colorant in a wide variety of commodities including printing inks, interior latex paints, lacquers, rubber, plastics, floor coverings, paper coatings, and textiles (NLM 2011).</td>
<td>No studies were found using biomarkers of exposure to 5-nitro-ortho-anisidine.</td>
</tr>
<tr>
<td>CAS</td>
<td>Name</td>
<td>Chemical group</td>
<td>Exposure summary</td>
<td>Biomarker summary</td>
</tr>
<tr>
<td>-------</td>
<td>-----------------------------</td>
<td>------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>92-87-5</td>
<td>Benzidine</td>
<td>Aromatic amine</td>
<td>Uses of benzidine and some related chemicals have decreased, particularly in the US and Europe, because they are known to cause bladder cancer in humans (NTP 2011). However many benzidine-based dyes are still produced and used in significant quantities in the US and elsewhere (US EPA 2010a). Benzidine-based and related dyes are used in the production of textiles, paints, printing inks, paper, and pharmaceuticals; as reagents and biological stains in laboratories; in the food industries; and in liquid crystal displays, laser and ink-jet printers, and electro-optical devices (US EPA 2010a). Some dyes used to color paper, cloth, leather, food and drinks may contain benzidine as a contaminant or other impurities that can be broken down into benzidine once inside the body (IARC 2010; NLM 2011).</td>
<td>Benzidine biomarkers can indicate exposure to benzidine and to benzidine-based azo dyes. Occupational studies have detected parent, metabolite, and adducted forms of benzidine in blood and urine, but more sensitive methods are in development in animal studies. Hemoglobin adducts have been detected in 33 exposed workers with GC-MS (Beyerbach et al. 2006). Older human occupational studies used 32P postlabeling on white blood cells, urine, and sputum in exposed workers and controls. Parent benzidine and two metabolites (N-acetylbenzidine and N,N'-diacetylbenzidine) were detected in worker’s urine with LODs in ppt via GC-MS (Hsu et al. 1996). Two NIOSH methods detect benzidine in urine via visible absorption/TLC extraction with estimated LOD 0.1 µg/dL urine (NIOSH 1993) and via GC-ECD, estimated LOD 5 µg/L, LLOQ 10 µg/L (NIOSH 1994a). Animal studies have measured DNA adducts with HPLC-MS/MS with LOD 22 pg on column (Means et al. 2003) and Birmer et al. (1990) identified several hemoglobin adducts including benzidine metabolite 4-aminobiphenyl. A more sensitive method has been developed on treated animal blood and tissue samples using supercritical fluid chromatography with LLOQ 0.10 ng/mL (Patel and Agrawal 2003).</td>
</tr>
<tr>
<td>6459-84-5</td>
<td>C.I. Acid Red 114</td>
<td>Aromatic amine</td>
<td>The general population may be exposed via dermal contact by direct dying of wool and silk using consumer products containing the compound (NLM 2004). C.I Acid Red 114 is used to dye wool, silk, jute, and leather. It is metabolized to 3,3’-dimethylbenzidine (NTP 2011). It is one of three components of commercial magenta which is used as a dye for coloring textiles (cotton, wool, silks, and acrylics), china clay products, leather, printing inks, and as a filter dye in photography. Its specialty applications include tinting automobile antifreeze solutions and toilet sanitary preparations (NTP 2011). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).</td>
<td>No studies were found using biomarkers to measure exposure to CI Acid Red 114.</td>
</tr>
<tr>
<td>569-81-9</td>
<td>C.I. Basic Red 9 monohydrochloride</td>
<td>Aromatic amine</td>
<td>Consumer exposure could possibly occur through contact with products containing residual dye (NTP 2011). C.I Basic Red 9 monohydrochloride is used to dye textile fibers, in the preparation of pigments for printing inks, and in other specialty applications (IARC 1993d). It is one of three components of commercial magenta which is used as a dye for coloring textiles (cotton, wool, silks, and acrylics), china clay products, leather, printing inks, and as a filter dye in photography. Its specialty applications include tinting automobile antifreeze solutions and toilet sanitary preparations (NTP 2011). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).</td>
<td>No studies were found using biomarkers to measure exposure to CI Basic Red 9 monohydrochloride.</td>
</tr>
<tr>
<td>1937-37-7</td>
<td>C.I. Direct Black 38</td>
<td>Aromatic amine</td>
<td>C.I. Direct Black 38 and other azo dyes are used on textiles such as cotton, silk, wool, nylon, acetate and leather, and used in aqueous printing inks and as biological stains, plastics, wood stains, wood flour, and hair dyes (NTP 1978b). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).</td>
<td>No studies were found using biomarkers specifically to measure exposure to C.I. Direct Black 38. Metabolites include benzidine, 4-aminobiphenyl, monoacetylbenzidine, and acetylaminobiphenyl; biomarker methods for benzidine could be used to assess exposure to C.I. Direct Black 38.</td>
</tr>
</tbody>
</table>
**CAS** | **Name** | **Chemical group** | **Exposure summary** | **Biomarker summary**
---|---|---|---|---
636-21-5 | Ortho-toluidine hydrochloride | Aromatic amine | The general population may be exposed to low concentrations of o-toluidine in ambient air, tobacco smoke, food, or dermal contact with commercial products (NTP 2011). Exposure has also been reported during its use in production of dyestuffs and rubber chemicals (IARC 2006a). It is listed as a Proposition 65 carcinogen (California OEHHA 2014). | Many studies have measured o-toluidine or its adducts in the blood and urine of the general population, smokers, patients receiving certain drugs, and exposed workers, and one study has measured o-toluidine in exhaled breath. Gaber et al. (2007) measured hemoglobin adducts of o-toluidine by GC-MS in blood collected from 10 surgical patients and 6 healthy volunteers before and 24 hours after receiving the anesthetic propofol and found hemoglobin adduct levels to increase from a baseline mean of 0.54 ng/g hemoglobin to a mean of 22 ng/g 24 hours after treatment, excluding one patient with very high initial levels (40.9 ng/g before, 64.4 ng/g after). Smoking status did not affect background or posttreatment levels. Kutting et al. (2009) found o-toluidine levels were significantly higher in the urine of smokers, with o-toluidine above the LOD in urine samples from 178 of 1004 Bavarian subjects. Riedel (2006), using GC-MS with negative ion chemical ionization, detected o-toluidine above the LOD of 4 ng/mL in 10 urine samples from non-smokers and 10 urine samples from smokers; smokers had higher levels. Label et al. (2006) used GC-MS with negative chemical ionization, with LOD 0.02 µL/g, to measure o-toluidine in 5 ml urine samples from workers involved in the demolition of an old chemical plant. Levels in samples from unexposed controls ranged from 0.17 to 2.46 µg/g creatinine, while levels in samples from exposed workers ranged from 26.17-462 µg/g, but went down to 2.35-20.11 ng/g after the introduction of new protective measures. Riedel et al. (2001) used proton transfer mass spectrometry for the measurement of VOCs including o-toluidine (which they describe as endogenously produced) in exhaled breath. |
26471-62-5 | Toluene diisocyanate mixtures | Aromatic amine | Because of the high volatility of toluene diisocyanates, exposure can occur in all phases of its manufacture and use. Exposure can occur from use of products containing unreacted TDI and related polycyanates, such as spray foam insulation and spray-applied sealants and coating, and incidental exposures to the general population while such products are used in or around buildings including homes or schools (US EPA 2011). Household products employing polyurethane varnishes or foam such as furniture, carpet underlay, and bedding may volatilize unreacted toluene diisocyanates. FDA has determined that levels of toluene diisocyanates in food, food additives, or food packaging are very low (NTP 2011). It is an EPA Action Plan Chemical, with exposures from building materials and some hobby products (US EPA 2013a). It is listed as a Proposition 65 carcinogen (California OEHHA 2014). | Biomarkers in blood and urine have been widely used to measure exposure to toluene diisocyanate in occupational and exposed-volunteer studies. The diamine derivative of TDI, toluene diamine (2,4-diaminotoluene) and the diamine derivatives of other diisocyanates can be detected after lysis from protein adducts in urine or blood through gas chromatography-mass-spectrometry, with LODs around 1 pmol per liter in urine (about 0.1 micromole diamine per mole creatinine) (Cocker 2011). Measurements of isocyanate derived diamines in blood and urine have been well correlated with TDI measurements in air in volunteer and occupational studies, but these measurements may reflect exposure to toluene diamine as well as toluene diisocyanate (Cooker 2011). Studies have also examined levels of TDI-albumin adducts and TDI-specific antibodies in serum (Brown and Burkert 2002). See reviews by Cocker et al. (2011) and Brown and Burkert (2002). See also methods for 2,4-diaminotoluene. |
71-43-2 | Benzene | Benzene | The primary sources of exposure to benzene for the general population are ambient air containing tobacco smoke, air contaminated with benzene, drinking contaminated water, or eating contaminated food (IARC 1982). Exposure to benzene is highest in areas of heavy motor vehicle traffic and around gasoline filling stations. Consumer products containing benzene include carpet, pesticide products, adhesive removers, and home-use paints, sealants, finishers, and auto oils (NLW 2013; NTP 2011). Major contributors to benzene emissions into air include: (1) gasoline production, storage, transport, vending and combustion; (2) production of other chemicals from benzene; and (3) indirect production of benzene (coke ovens), which is a major source of benzene emissions into water (IARC 1982). Benzene is a TSCA Work Plan Chemical, identified as having a high likelihood of exposure. It is present in biomonitoring, drinking water, indoor environments, and soil, and high releases to the environment have been reported (US EPA 2012). It is on the Canadian Priority Substances List, with exposures from ambient air, cigarette smoke, and to a lesser extent, food and consumer products (Health Canada 2007a) It is listed as a Proposition 65 carcinogen (California OEHHA 2014). | NHANES and others have measured benzene in blood samples taken from the general population, generally detecting benzene in all or most samples. Other researchers have measured unmetabolized benzene in urine and breath, benzene metabolites in urine, and adducts to proteins and DNA in blood and dried blood spots. NHANES detected benzene in over half the population via HS-SPME-GC-MS on 3 mL (minimum) to 10 mL (optimal) whole blood, with LOD 0.024 ng/mL (Blount et al. 2006; CDC 2009b, 2009). CDC is planning to add UPLC-ES-MS/MS testing for the urinary benzene metabolites trans trans muconic acid (ttMA; LOD 12 ng/mL) and s-phenyl mercapturic acid (sPMA; LOD 0.3 ng/mL) to future NHANES reports (Alvis et al. 2012). A CDC pilot study found that ttMA and sPMA levels were significantly higher in smokers than in non-smokers (Alvis et al. 2012). Unmetabolized benzene can be measured in blood, urine, and breath samples from the general population by purge and trap, headspace, SPE, or SPME extraction followed by GC-MS, with LODs in pg/mL (Weisel 2010), but it has a half-life of only minutes to hours, and samples can easily become contaminated with benzene from the environment (Johnson et al. 2007). Nonetheless, benzene levels in blood can differentiate between exposed and unexposed workers, smokers and non-smokers, and pre- and post-shift samples, and urinary benzene levels were associated with workplace air benzene concentrations in at least one study (Weisel 2010). Hemoglobin, albumin, and DNA adducts have also been measured, with much longer half-lives (2 to 3 weeks for albumin adducts, about 4 months for hemoglobin adducts, and longer for DNA) (Johnson et al. 2007; Weisel 2010). Funk et al. (2008) demonstrated that benzene oxide-hemoglobin adducts could be measured in dried blood spots by GC-MS. Urinary metabolites ttMA and sPMA have been measured by SPE or SPME followed by HPLC-UV, HPLC-MS/MS, or GC-MS, typically with LODs between 5-10 µg/L (Weisel 2010). Both are generally well correlated with benzene exposures from 0.1-20 ppm, but ttMA is also a metabolite of the food additive sorbic acid, whereas sPMA has no known sources besides benzene (Weisel 2010). Researchers have also measured the urinary benzene metabolites phenol, catechol, and hydroquinone via liquid extraction, SPE, or SPME followed by GC FID, GC-MS, HPLC UV, or HPLC-MS/MS (Weisel 2010).
tris(2,3-dibromopropyl) phosphate. Based on studies with the chlorinated analog of this flame retardant, tris(dichloropropyl)phosphate, the

**CAS** 75-21-8  Ethylene oxide  Ethylene oxide  The general population may be exposed to ethylene oxide (EO) through use of products that have been sterilized with the compound, such as medical products, foods, clothing, cosmetics, beekeeping equipment, and other products. EO has been detected in tobacco smoke, automobile exhausts, and in some foods and spices (NTP 2011). It is found in household rust neutralizer, driveway cleaner, and transmission fluid (NLM 2013). It is on the Canadian Priority Substances List, with exposures from indoor air, food, spices, and medical equipment sterilized with EO seen (Environment Canada 2011). It is listed as a Proposition 65 carcinogen (California OEHHA 2006c; NTP 2011). It is listed as a Proposition 65 carcinogen (California OEHHA 2014). It is on the REACH SVHC Candidate List, with low exposures from the environment as dust and through wastewater.

Methods for detecting urinary metabolites, DNA adducts, and hemoglobin adducts of ethylene oxide (EO) have been employed in occupational and general population studies. NHANES has measured 2-hydroxymethyl mercapturic acid (HHEMA), a common metabolite of 1,2-dibromomethane, vinyl chloride, acrylonitrile, and EIO, in urine by isotope dilution and HPLC-MS/MS, detecting it in 71% of samples.

No studies were found using biomarkers to measure exposure to bis(bromomethyl)-1,3-propanediol in humans. A pharmacokinetic study in rats found that the main route of excretion was as a glucuronide metabolite in urine (Hoehle et al. 2009), but humans are much slower than rats at producing the glucuronide metabolite. Possibly this compound could be measured using a GC-MS method that also can measure 2,3-dibromopropanol (De Alwis et al. 2007) or an LC-MS/MS method for bis(1,3-dichloro-2-propyl) phosphate (BDCPP), a metabolite of a chlorinated tris organophosphate flame retardant (Cooper et al. 2011).

2,3-dibromopropanol (DBP) has been measured in urine. De Alwis et al. (2007) used SPE-GC-MS on spiked human urine, reporting 86% recovery and LOD 0.1 ng/ml. Blum et al. (1978) detected DBP in urine of children wearing pajamas treated with the flame retardant (2,3-dibromopropyl) phosphate. Based on studies with the chlorinated analog of this flame retardant, tris(dichloropropyl)phosphate, the bis-metabolite may be more stable and easier to detect in urine via LC-MS/MS (Cooper et al. 2011).

**CAS** 75-56-9  Propylene oxide  Propylene oxide  General population exposure may occur through ingestion of propylene oxide residues in foods from its use as an indirect registered food additive (US FDA 2013) and tobacco smoke. Exposure may also occur by contact with consumer products containing the chemical, especially automotive and paint products which have been found to contain high concentrations of PO. It is also used to manufacture polyurethane foam (NTP 2011). It is listed as a Proposition 65 carcinogen (California OEHHA 2014). It is on the REACH SVHC Candidate List, with low exposures from the environment and consumer products, such as brake fluid (ECHA 2013).

CDC has developed a method to measure PO exposure in urine from the general population. A number of studies have used biomarkers in blood and urine to investigate exposure to PO in occupationally- or tobacco-exposed humans and controls with no known exposure, and one study measured PO in the exhaled breath of humans intentionally exposed to propylene. CDC is planning to add UPLC-ES-MS/MS testing for urinary HEMA (LOD 0.6 ng/ml) to future NHANES reports (Alwis et al. 2012). CDC currently measures acrylamide- and glycidimide-derived hemoglobin adducts in blood and plans to add EIO adducts to the method (CDC 2008a). Tomkins et al. (2008) measured five ethylene oxide-derived hydroxethyl DNA adducts via HPLC-LC-MS/MS (SRM), with LODs 0.5-26 fmol. Yong et al. (2007) detected DNA adducts in granulocytes in blood from hospital workers using HPLC-GC-EC-MS. The lowest concentration of adducts was 1.6 ppm 10^7 nucleotides. They note that adducts in lymphocytes would be more informative for longer term (up to one year) exposures. Huang et al. (2008) looked for the same adduct (N7 (2-hydroxyethyl)guanine) in urine of nonsmokers, and detected adducts in 40/46 samples with LOD 0.26 nmol/µL using LC-MS/MS. Yong et al. (2007) warns that since DNA adducts are thought to have a short half-life, hemoglobin adducts may be more useful for understanding long term exposures. von Stedingk et al. (2010) developed a method for detecting hemoglobin adducts by LC-MS/MS with LLOQ 1 pmol/µg Hb. A GC-EI-MS method has LOD 1.8 pmol/µg in 0.1 g hemoglobin and LLOQ 12 pmol/µg in human blood samples (Ahn and Shin 2006). The 95th percentile for N-(2-hydroxyethyl)valine (HEV) was 1280 pmol/µg (±29.4 microg/l blood) in blood from exposed workers compared with 100 pmol/µg (or 2.3 microg/l) in controls (Schettgen et al. 2002). HEMA was measured in urine from non-smokers (median 2 µg/L) and smokers (median 5.3 µg/L) via HPLC-MS/MS with LOD 0.5 µg/L (Schettgen et al. 2008).

**CAS** 3296-90-0  2,2-Bis(bromomethyl)-1,3-propanediol  Flame retardant  The primary routes of exposure to bis(bromomethyl)-1,3-propanediol are inhalation and dermal contact. It is a flame retardant used in polyester resins and polyurethane foams and may enter the environment as dust and through wastewater. It is expected to be persistent in water (IARC 2000c; NTP 2011). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).

No studies were found using biomarkers to measure exposure to bis(bromomethyl)-1,3-propanediol in humans. A pharmacokinetic study in rats found that the main route of excretion was as a glucuronide metabolite in urine (Hoehle et al. 2009), but humans are much slower than rats at producing the glucuronide metabolite. Possibly this compound could be measured using a GC-MS method that also can measure 2,3-dibromopropanol (De Alwis et al. 2007) or an LC-MS/MS method for bis(1,3-dichloro-2-propyl) phosphate (BDCPP), a metabolite of a chlorinated tris organophosphate flame retardant (Cooper et al. 2011).

**CAS** 96-13-9  2,3-Dibromo-1-propanol  Flame retardant  The primary routes of exposure are inhalation and dermal contact. DBP is a metabolite and degradation product of tris(2,3-dibromopropyl) phosphate, a flame retardant that was used in children's sleepwear in the 1970s. DBP was detected in urine of children wearing sleepwear treated with Tris (NTP 2011). DBP is also a potential metabolite, impurity, and degradation product of a newer flame retardant, tetrabromobisphenol A (bis(2,3-dibromopropyl ether), which is an HPV chemical that has been proposed for carcinogenicity testing at NTP (Hanneke 2002). DBP is a listed Proposition 65 carcinogen (California OEHHA 2014).

No studies were found using biomarkers to measure exposure to bis(bromomethyl)-1,3-propanediol in humans. A pharmacokinetic study in rats found that the main route of excretion was as a glucuronide metabolite in urine (Hoehle et al. 2009), but humans are much slower than rats at producing the glucuronide metabolite. Possibly this compound could be measured using a GC-MS method that also can measure 2,3-dibromopropanol (De Alwis et al. 2007) or an LC-MS/MS method for bis(1,3-dichloro-2-propyl) phosphate (BDCPP), a metabolite of a chlorinated tris organophosphate flame retardant (Cooper et al. 2011).

2,3-dibromopropanol (DBP) has been measured in urine. De Alwis et al. (2007) used SPE-GC-MS on spiked human urine, reporting 86% recovery and LOD 0.1 ng/ml. Blum et al. (1978) detected DBP in urine of children wearing pajamas treated with the flame retardant (2,3-dibromopropyl) phosphate. Based on studies with the chlorinated analog of this flame retardant, tris(dichloropropyl)phosphate, the bis-metabolite may be more stable and easier to detect in urine via LC-MS/MS (Cooper et al. 2011).
<table>
<thead>
<tr>
<th>CAS</th>
<th>Name</th>
<th>Chemical group</th>
<th>Exposure summary</th>
<th>Biomarker summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>75-34-3</td>
<td>1,1-Dichloroethane</td>
<td>Halogenated organic solvent</td>
<td>The general population may be exposed via inhalation (for those people living near source areas), ingestion of contaminated drinking water, and use of consumer products, such as paint removers, that may contain this compound (NLM 2011). This chemical is a TSCA 2013/2014 Work Plan Chemical, identified as having a high likelihood of exposure. It is used in consumer products and present in drinking water, surface water, ambient air, groundwater, soil, and biomonitoring. Moderate releases to the environment have been reported (US EPA 2012). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).</td>
<td>NHANES has used HS-SPME-GC-MS on 3 mL (minimum) to 10 mL (optimal) whole blood, but less than 5% of the population had levels above the LOD of 0.01 ng/mL (Blount et al. 2006; CDC 2008b, 2009). Possibly a method to measure non-specific urine metabolites such as haloacetic acids and haloalcohols could be developed.</td>
</tr>
<tr>
<td>96-18-4</td>
<td>1,2,3-Trichloropropane</td>
<td>Halogenated organic solvent</td>
<td>The general population may be exposed by ingestion of contaminated well water or by inhalation of contaminated air (NTP 2011). Detected in water, including drinking-water, and in soil as a result of its presence as an impurity in a commercial nematocide. Formerly produced as paint and varnish remover and as a cleaning and degreasing agent. Also formerly used as soil fumigant, until 1991 (IARC 1994). It is listed as Proposition 65 carcinogen (California OEHHA 2014). It is listed on the REACH SVHC Candidate list as carcinogenic and toxic for reproduction, with exposures from air and water from the production of chlorinated compounds (ECHA 2011a).</td>
<td>No studies were found using biomarkers of exposure to 1,2,3-trichloropropane.</td>
</tr>
<tr>
<td>106-93-4</td>
<td>1,2-Dibromoethane</td>
<td>Halogenated organic solvent</td>
<td>For the general population, the most important current exposure is through contaminated drinking water due to 1,2-dibromoethane's former use as a gasoline additive (NTP 2011). It was also used historically and is still used outside of the US as a pesticide, and exposure may also occur in pest control, petroleum refining and waterproofing. It has been detected in ambient air, soil, groundwater, and food. Historically, concentrations in ambient air were an important source of exposure, especially near automobiles or filling stations (IARC 1999f; NTP 2011). This is a TSCA Work Plan Chemical, identified as a low likelihood of exposure. It is used in commercial and industrial products and present in indoor environments and soil. Relatively small releases to the environment have been reported (US EPA 2012). It is listed as Proposition 65 male developmental toxicant (California OEHHA 2014).</td>
<td>No studies were found using specific biomarkers of exposure to 1,2-dibromoethane, although NHANES measured 2-hydroxyethyl mercapturic acid (HEMA), a common metabolite of 1,2-dibromoethane, vinyl chloride, acrylonitrile, and ethylene oxide, in urine by isotope dilution and HPLC-MS/MS, detecting it in 71% of samples, with higher levels in smokers (Calafat et al. 1999).</td>
</tr>
<tr>
<td>CAS</td>
<td>Name</td>
<td>Chemical group</td>
<td>Exposure summary</td>
<td>Biomarker summary</td>
</tr>
<tr>
<td>--------</td>
<td>--------------------</td>
<td>---------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>107-06-2</td>
<td>1,2-Dichloroethane</td>
<td>Halogenated organic solvent</td>
<td>The greatest source of exposure to 1,2-dichloroethane for the general population is inhalation of the compound in contaminated air (NTP 2011). It has been detected at low levels in ambient and urban air, groundwater and drinking water due to its former use as a gasoline additive, and it has also been detected in food items, possibly due to its use as an extractant in certain food processes (IARC 1999; NTP 2011). It is mainly used in the production of vinyl chloride and is a biodegradation product of tetrachloroethane. It is used in some consumer products (adhesives, rug cleaners), and it was historically used as a fumigant (IARC 1999; NTP 2011). It is a TSCA 2013/2014 Work Plan Chemical, identified as a low likelihood of exposure. It is used in commercial and industrial products, present in biomonitoring, and high releases have been reported to the environment (US EPA 2012). It is listed on the Canadian Priority Substances List, with exposures from ambient and indoor air, surface waters, groundwaters, and drinking water (Health Canada 1994). It is listed as a Proposition 65 carcinogen (California OEHHA 2014). It is listed on the REACH SVHC Candidate List as carcinogenic, with exposures from ambient and urban air, groundwater and drinking-water samples (ECHA 2011b).</td>
<td>NHANES has used HS-SPME-GC-MS on 3 mL (minimum) to 10 mL (optimal) whole blood, but less than 5% of the population had levels above the LOD of 0.01 ng/mL (Blount et al. 2006; CDC 2008b, 2009). Possibly a method to measure non-specific urine metabolites such as haloacetic acids and haloalcohols could be developed.</td>
</tr>
<tr>
<td>78-87-5</td>
<td>1,2-Dichloropropane</td>
<td>Halogenated organic solvent</td>
<td>The general population may be exposed via inhalation of ambient air, ingestion of drinking water, and dermal contact with consumer products containing 1,2-dichloropropane (IARC 1986a; NLM 2011). This is a TSCA 2013/2014 Work Plan Chemical, identified as having a high likelihood of exposure. It is used in consumer products and present in biomonitoring, drinking water, indoor environments, and soil. High releases to the environment have been reported (US EPA 2012). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).</td>
<td>NHANES has measured 1,2-dichloropropane in blood samples from the general population, and others have attempted to measure it in the blood of occupationally exposed populations. NHANES has used HS-SPME-GC-MS on 3 mL (minimum) to 10 mL (optimal) whole blood, but less than 5% of the population had levels above the LOD of 0.008 ng/mL (Blount et al. 2006; CDC 2008b, 2009). Occupationally, unmetabolized 1,2-dichloropropane measured by SPME-GC-MS was below the LOD (0.2 µg/L) in the urine of 9 &quot;handicraft&quot; automobile mechanics (Vitali et al. 2006). Possibly a method to measure non-specific urine metabolites such as haloacetic acids and haloalcohols could be developed.</td>
</tr>
<tr>
<td>56-23-5</td>
<td>Carbon tetrachloride</td>
<td>Halogenated organic solvent</td>
<td>The general population is most likely exposed to carbon tetrachloride through air and drinking water (NTP 2011). It may be used in paint and varnish remover, cleaning and sanitation products, auto products, and hobby/craft products, and it is found in household plastic and epoxy binders (NLM 2013). It was formerly used as dry cleaning agent, aerosol propellant, pesticide/fumigant and fire extinguisher (NLM 2011). It is detected at low levels in ambient air and water (IARC 1999a). It is a TSCA Work Plan Chemical, identified as low likelihood of exposure. It is present in drinking water and soil. High releases to the environment have been reported (US EPA 2012). It is a Proposition 65 carcinogen (California OEHHA 2014).</td>
<td>NHANES has used HS-SPME-GC-MS on 3 mL (minimum) to 10 mL (optimal) whole blood, but less than 5% of the population had levels above the LOD of 0.005 ng/mL (Blount et al. 2006; CDC 2008b, 2009). Occupationally, carbon tetrachloride has been measured in urine (Gobba et al. 1997), and a method to measure non-specific urine metabolites such as haloacetic acids and haloalcohols could be developed.</td>
</tr>
</tbody>
</table>
75-09-2  Methylene chloride (dichloromethane)  Halogenated organic solvent  Widespread exposure occurs during the production and industrial use of methylene chloride and during the use of a variety of consumer products containing it. Consumer products that may contain the chemical include: fabric cleaners, furniture polish, paint strippers, wood sealant and stains, spray paints, adhesives, shoe polish, art supplies, (US EPA 2010b) and biomarkers favor and many home maintenance and craft products (NLM 2013). It was used until 1989 as a propellant for hair spray. Substantial losses to the environment lead to ubiquitous low-level exposures from ambient air and groundwater (ARC 1999; NTP 2011). It is a TSCA 2012 Work Plan Chemical, identified as having a high likelihood of exposure. It is present in drinking water, indoor environments, and soil. High releases to the environment have been reported (US EPA 2012). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).

Methylene chloride has been measured in blood, urine, and exhaled breath in population and occupational studies. NHANES has used HS-SPME-GC-isotope dilution MS on 3-10 mL whole blood, but less than 5% of the population had levels above the LOD 0.07 ng/mL (Blount et al. 2006; CDC 2008b, 2009). Smith et al. (2008) measured methylene chloride and other VOCs via HS SPE GC-MS in urine from 24 healthy elderly men, detecting methylene chloride in all samples; methylene chloride was still detectable after 8 hours from unfrozen storage. Poli et al. (2005) used HS SPME GC-MS with LOD 0.005 µg/L to measure methylene chloride in urine from 120 unexposed individuals, with a median concentration of 0.68 µg/L. In two cases of acute methylene chloride poisoning, Poli et al. (2005) calculated urinary half-lives of 7.5 and 3.8 hours, and blood half-lives of 4.3 and 8.1 hours. Hoff er et al. (2005), using HS SPME-GC, found 0.020-0.06 mg/L methylene chloride in urine from 7 exposed workers. Based on experiments with spiked urine, they stress the importance of promptly sealing urine collection and headspace chamber containers, and of analyzing samples within 2 weeks of collection. Sakai et al. (2002) used HS GC-FID with LOD 0.01 mg/L, and found that exposure levels and urinary concentrations were highly correlated in an occupationally exposed group. Delfino et al. (2003) detected methylene chloride in over 75% of 106 exhaled breath samples from 21 Hispanic children with mild asthma living near major sources of vehicle exhaust in LA, but found that ambient VOC measurements were better predictors of symptoms than VOCs in exhaled breath. Thrall et al. (2001) found that concentrations in exhaled breath samples from exposed workers increased by up to 573 ppb after performing tasks involving methylene chloride. Possibly a method to measure non-specific urine metabolites such as haloacetic acids and haloalcohols could be developed.

75-01-4  Vinyl chloride  Halogenated organic solvent  The general population may have some limited exposure to vinyl chloride, particularly through direct or indirect contact with polymer products (ARC 1979). It is used almost exclusively by the plastics industry to produce polyvinyl chloride (PVC), a plastic used in many consumer and industrial products. It was previously used as a refrigerant and in aerosol propellants, including hairsprays, but these uses were banned in 1974 (NTP 2011). It is a TSCA 2012 Work Plan Chemical, identified as having a high likelihood of exposure. It is present in drinking water, indoor environments, surface water, ambient air, groundwater, and soil. High releases to the environment have been reported (US EPA 2012). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).

Two studies were found using urine biomarkers of exposure to vinyl chloride (VC), one in the general population, one in an occupational setting. In addition, NHANES has measured 2-hydroxyethyl mercapturic acid (HEMA), a common metabolite of 1,2-dibromoethane, vinyl chloride, acrylonitrile, and ethylene oxide, in urine by isotope dilution and HPLC/MS/MS, detecting it in 71% of samples, with higher levels in smokers (Calafat et al. 1998). CDC is planning to add UPLC-ESI-MS/MS testing for HEMA (LOD 0.6 ng/mL) to future NHANES reports (Alvis et al. 2012). Gonzalez-Reche et al. (2002) used HPLC-ESI-MS/MS (and confirmatory GC-MS) to detect etheno-DNA adducts (1,N2-ethenoguanine, N2,3-ethenoguanine), in urine from 13 healthy subjects without known occupational exposure to industrial chemicals such as VC and ethyl carbamate, exposure to both of which forms such adducts. They found adducts in the range <0.3-8 nmol/L, and proposed endogenous mechanisms for the formation of adducts at these “background” levels. Chang et al. (2001) measured levels of the VC metabolite thioglycidic acid (TdGA) in the urine of 16 PVC manufacturing workers at the end of one shift and at the beginning of the next. They found a significant difference in TdGA levels for workers exposed to more than v less than 5 ppm VC, and a significant correlation between air VC concentration and urinary TdGA concentration. TdGA levels were higher at the beginning of a shift than at the end of the previous one.

75-02-5  Vinyl fluoride  Halogenated organic solvent  Vinyl fluoride is used in the production of polyvinylfluoride which has been used to cover walls, pipes, and electrical equipment and inside aircraft cabins (NTP 2011). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).

No studies were found using biomarkers for vinyl fluoride.

75-35-4  Vinylidene chloride  Halogenated organic solvent  The general population may be exposed via inhalation of ambient air, ingestion of food and drinking water, and dermal contact with consumer products, such as plastic wrap which contains residual monomer (NLM 2011). Migration of vinylidene chloride into food wrapped in plastic is likely. It is detected in wastewater (ARC 1999).

NHANES has used HS-SPME-GC-MS on 3-10 mL whole blood, but less than 5% of the population had vinylidene chloride levels above the LOD of 0.009 ng/mL (Blount et al. 2006; CDC 2008b, 2009). Waksman and Phillips (2004) briefly review research on the metabolism and biomonitoring of vinylidene chloride, noting that metabolites such as dihydroxyacrylic acid are sometimes used, but that many DCE metabolites are also metabolites of other chlorinated hydrocarbons.

62450-07-1  3-Amino-1-methyl-5h-pyrind[4,3-b]indole (Trp-P-2)  Heterocyclic amine  Consumption of charred fraction of cooked fish is a source of exposure for the general population (ARC 1983b). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).

Trp-P-2 has been measured in the blood, urine, and bile of healthy volunteers and hospital patients. Manabe et al. (1992) used HPLC on plasma and red blood cells from healthy volunteers and patients with uremia, detecting Trp-P-2 at 2 higher levels in uremic patients but also detecting it in samples from healthy subjects. Ushiyama et al. (1991) used HPLC on urine from 10 healthy volunteers on “normal” diets (3 patients on IV feeding). Trp-P-2 levels ranged from 0.03-0.68 ng in 24 hr urine samples from healthy volunteers, with non-detect in the patients’ urine. Using HPLC on human bile from seven subjects with catheterized bile ducts and external biliary drainage, Manabe et al. (1990) found an average of 864 fmol Trp-P-2 excreted per day. Baranczewski et al. (2004) was able to detect Trp-P-2-DNA adducts in the livers of mice dosed with Trp-P-2.

76180-96-6  2-Amino-3-methylimidazo[4,5-f]-quinoxine (IQ)  Heterocyclic amine  Exposure occurs primarily through the consumption of cooked meats; it is also detected in processed food flavorings, beer, wine, and cigarette smoke (ARC 1993a; c; NTP 2005). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).

No studies were found using biomarkers to measure exposure to IQ in humans, though methods have been developed for measuring IQ and its metabolites in urine. Yokall et al. (2004) developed a method for the extraction of IQ and other heterocyclic amines from human urine using blue rayon. Gerbit et al. (2004) describes HPLC with coulometric electrode array detection for measurement of IQ in rat urine. Hsu et al. (2009) and Lakshmi et al. (2009) identify multiple metabolites in the urine of mice dosed with IQ.
77094-11-2
2-Amino-3,4-dimethylimidazo(4,5-f)quinoline (MeIQ)
Heterocyclic amine
Exposure occurs primarily through the consumption of cooked meats. MeIQ is also detected in processed food flavorings, beer, wine, and cigarette smoke (NLM 2011; NTP 2011). The associated chemical MeIQx has also been found in air and surface water (NTP 2011). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).

105650-23-5
PhIP
Heterocyclic amine
Exposure occurs primarily through the consumption of cooked meats, and PhIP has also been detected in processed food flavorings, beer, wine, and cigarette smoke. It is present in air and surface water (NTP 2011). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).

81-11-8
Amsonic acid
Hormone or EDC
Potential sources of exposure include clothing, especially when moistened by perspiration, packaging materials, some foods, such as fish, and insufficiently rinsed dishes. There is little if any direct use of the parent compound by consumers. It is used in the manufacture of dyes and fluorescent whitening agents or optical brighteners with a range of uses, including in laundry detergents (NTP 1992).

8112-24-9
Atrazine
Hormone or EDC
The general population may be exposed to atrazine via inhalation of ambient air, ingestion of drinking water, and ingestion of foods that may contain atrazine (NLM 2011). It is a commonly used herbicide and found widely, together with its dealkylated degradation products, in rivers, lakes, estuaries, groundwater and reservoirs (IARC 1999g).

NHANES, NIOSH, and others have measured atrazine and its metabolites in urine of the general population and exposed farmers. NHANES 2003-2004 measured atrazine and 5 metabolites in urine samples from the general population, but has withdrawn those data "due to unacceptable measurement variance at or near the LOD" (CDC 2011) NHANES 2001-2002 measured urinary atrazine mercapturate, which was not detectable in most samples over the LOD of ~1 µg/L (CDC 2009). NIOSH method 8315, exposure to triazine herbicides (NIOSH 2003) measures atrazine, desethyl atrazine, and desisopropyl atrazine via GC-MS in at least 15 mL urine, LOD 20-47 nmoL. Panuwet et al. (2010) developed a method using SPE-HPLC-MS/MS with isotope dilution quantification to measure atrazine and 6 metabolites, with LODs between 0.05-0.19 ng/mL. Curwin et al. (2010) describes immunoassay to quantify atrazine mercapturate and other pesticide metabolites as cheaper and faster than HPLC-MS/MS but more likely to overestimate exposure. Barr et al. (2007) used SPE-HPLC-MS/MS to measure atrazine and 9 metabolites in urine from a small sample of people with varied exposure levels, and found highly varied metabolite profiles, concluding that it is important to measure multiple metabolites, that measuring only atrazine and atrazine mercapturate underestimates atrazine exposure, and that the most informative metabolites are diaminochloro(propyl) triazine and desethylatrazine. Chevrier et al. (2011) measured multiple atrazine metabolites, detecting atrazine or atrazine mercapturate in the urine of 5.5% of pregnant women (n=579) in Brittany in 2002-2006, while dealkylated and hydroxylated triazine metabolites were detectable in 29% and 41% of samples respectively. Multiple studies (Bakke et al. 2009; Curwin et al. 2010; Mendes et al. 2012) have measured atrazine mercapturate in the urine of farm workers, their families, and controls, and have found that elevated levels persist after pesticide application.
<table>
<thead>
<tr>
<th>CAS</th>
<th>Name</th>
<th>Chemical group</th>
<th>Exposure summary</th>
<th>Biomarker summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>12789-03-6</td>
<td>Chlordane</td>
<td>Hormone or EDC</td>
<td>Although use of this organochlorine insecticide has been banned, human exposure continues because of its persistence in the environment, especially in indoor air in previously treated buildings and in meat, fish and other fat-containing foodstuffs (IARC 2001b). It was used starting in the 1950s for termite control, on agricultural crops, on lawns, on livestock, and for other purposes, and is commonly detected in indoor air and house dust in the US (Rudel et al. 2003).</td>
<td>NHANES and others have measured chlordane and its metabolites in the blood of the general population, and some studies have measured chlordane or its metabolites in human breast milk and adipose tissue. NHANES measured the chlordane metabolites oxychlordane and trans-nonachlor in serum via SPE followed by gas chromatography/isotope dilution high-resolution mass spectrometry (CDC 2006; 2013; Everett and Matheson 2010; Lee et al. 2006) in 1999-2001, 2001-02, and 2003-04. Others have also measured cis-chlordane, trans-chlordane, and cis-nonachlor in blood (Cao et al. 2012; Rudge et al. 2012; Varona et al. 2010). Many studies (Haraguchi et al. 2009; Medley et al. 2010; Tanabe and Kunisue 2007; Zhou et al. 2011) have used GC-MS or other methods to measure chlordane or chlordane related chemicals in human breast milk, mostly in Asia. A few researchers have measured chlordane in human adipose tissues (Kunisue et al. 2006; Kutz et al. 1991; Nakata et al. 2005).</td>
</tr>
<tr>
<td>NA</td>
<td>Conjugated estrogens</td>
<td>Hormone or EDC</td>
<td>Conjugated estrogens can be measured in domestic wastewater and surface water polluted by wastewater, following urinary excretion. They are used for estrogen replacement therapy and oral contraceptives (Kolpin et al. 2002). The use of postmenopausal estrogen therapy became common in the United States in the 1960s. By 1967, approximately 13% of the women in the United States 45 to 64 years old used this type of therapy. The number of prescriptions for estrogens, not counting those used for oral contraceptives, increased from approximately 15 million in 1966 to more than 25 million in 1976, when prescriptions declined because of concerns about endometrial cancer, but then increased rapidly to approximately 40 million by 1992. In 2002, more than 100 million prescriptions were filled for brand-name and generic products containing estrogens (either conjugated or esterified) as an active ingredient (NTP 2011). Observed increased breast cancer risk associated with exposure to pharmaceutical estrogens has raised concern about possible risk associated with chemicals that mimic estrogen or are endocrine disruptors. Most commercial chemicals have not been screened for endocrine disruption. Also, as discussed by Rudel et al. (2007; 2011), the typical cancer bioassay design may not be sensitive to hormonally-induced mammary tumors. Conjugated estrogens are listed as Proposition 65 carcinogens (California OEHHA 2014).</td>
<td>See summary for estradiol. Many methods used to measure non-conjugated estrogens can also measure conjugated estrogens in blood and urine either by quantifying the conjugated forms specifically via LC-MS/MS and presumably GC-MS/MS (Ziegler et al. 2010), or by subtracting concentrations of unconjugated hormone from total hormone concentration measured after lysis of the conjugate groups (Blair 2010).</td>
</tr>
<tr>
<td>CAS</td>
<td>Name</td>
<td>Chemical group</td>
<td>Exposure summary</td>
<td>Biomarker summary</td>
</tr>
<tr>
<td>-------</td>
<td>--------------------</td>
<td>----------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>56-53-1</td>
<td>Diethylstilbestrol</td>
<td>Hormone or EDC</td>
<td>DES is a synthetic estrogen that was prescribed to pregnant women from the 1950s until the early 1970s to prevent miscarriage. It was later shown to be a transplacental carcinogen, causing a rare vaginal cancer in daughters of exposed women. It has been demonstrated to increase breast cancer risk in exposed mothers and their daughters, and to cause reproductive system abnormalities (Hoover et al. 2011). An estimated 5-10 million people were exposed in utero in the US (ARC 2012; NTP 2011). DES is now occasionally used to treat prostate cancer, but this use is rare because of its side-effects. It is occasionally used in postmenopausal women with breast cancer (ARC 2012). It has also been found in animal feed (NLM 2004) and was historically used as a growth promoter in sheep and cattle (NTP 2011). It is listed as a Proposition 65 carcinogen and developmental toxicant (California OEHHA 2014).</td>
<td>A few studies have described methods for measurement of DES in human urine, and more have measured it in bovine urine. Zou et al. (2012) used HPLC with novel extraction methods to detect DES with LOD 0.1 ng/mL in human urine, while Wu et al. (2009) used GC-MS in human urine, with a limit of detection of 0.28 ng/mL, and concluded that their method was sufficiently sensitive to use for &quot;routine assessment and monitoring... in the human body&quot;. Measurements of DES in bovine urine have used LC-MS/MS (Kaklamanos et al. 2009; Schmidt et al. 2008), HPLC-MS (Rubies et al. 2007), LC-ES-MS (Msagati and Nindi 2006) and GC-MS (Aman et al. 2006; Dickson et al. 2003).</td>
</tr>
<tr>
<td>50-28-2</td>
<td>Estradiol-17b</td>
<td>Hormone or EDC</td>
<td>Estradiol can be measured in domestic wastewater and surface water polluted by wastewater, following urinary excretion (Kolpin et al. 2002). It is used pharmaceutically as an estrogenic hormone, estrogen replacement therapy, and oral contraceptive (NLM 2011). Monitoring data indicate that the general population may be exposed to estradiol at levels below the therapeutic dose via ingestion of drinking water and dermal contact with contaminated sediments (NLM 2004). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).</td>
<td>Clinical and research laboratories have used many methods to measure estradiol and other steroid hormones in human blood and urine. &quot;Direct&quot; radio immunoassay (RIA), with no extraction or chromatography steps, is commonly used to measure estradiol in serum or plasma in clinical practice, but is imprecise and prone to interference from other hormones and hormone-binding proteins in serum or plasma (Blair 2010; Cao et al. 2004; Rosner et al. 2013). Additionally, standard direct RIA can't detect the low levels found in small blood samples from people other than healthy premenopausal adult women (Blair 2010; Rosner et al. 2013). HPLC-RIA is somewhat more sensitive and precise, but suffers from many of the same problems as direct RIA (Blair 2010). GC-MS and LC-MS methods in blood and urine are more precise, sensitive, and specific, but many require specialized derivatization and ionization steps to achieve low detection limits (Blair 2010; Rosner et al. 2013; Stanczyk and Clarke 2010). Additional reviews are available (Honour 2006, 2010; Kushnir et al. 2010; McDonald et al. 2011; Taylor 2006). The development of methods to conduct a similar assay in blood, and to distinguish endogenous and exogenous estrogen signals, would allow integrated assessments of exposure to xenoestrogens.</td>
</tr>
<tr>
<td>53-16-7</td>
<td>Estrone</td>
<td>Hormone or EDC</td>
<td>Unspecified estrogen and estrogenic hormones, which are believed to consist primarily of estrone, have been used in hormonal skin preparations (less than 0.1% to 5%), moisturizing lotions (1% to 5%), wrinkle-smoothing creams, hair conditioners, hair straighteners, shampoos, and grooming aid tonics (less than 0.1%) (NTP 2011). There are case reports of children with premature breast development associated with these exposures. It is listed as a Proposition 65 carcinogen (California OEHHA 2014).</td>
<td>See summary for estradiol. Methods used to measure estradiol can also measure estrone (Blair 2010; Stanczyk and Clarke 2010; Ziegler et al. 2010).</td>
</tr>
<tr>
<td>CAS</td>
<td>Name</td>
<td>Chemical group</td>
<td>Exposure summary</td>
<td>Biomarker summary</td>
</tr>
<tr>
<td>---------</td>
<td>-------------------------------</td>
<td>----------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>57-83-0</td>
<td>Progesterone</td>
<td>Hormone or EDC</td>
<td>Human placental extracts, of which progesterone is believed to be the main constituent, have been used in preparations for cosmetic use (at levels of 0.1% to 1.0%), hair conditioners, shampoos, and grooming aid tonics (&lt;0.1%). There are case reports of children with premature breast development associated with these exposures. Progesterone has been detected in cow’s milk, milk products, certain plant species, and meat from animals treated with a progesterone implant. Progesterone is also used in pharmaceuticals including birth control (NTP 2011). Monitoring data indicate that the general population may be exposed to progesterone at well below the therapeutic dose via ingestion of drinking water (NLM 2011). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).</td>
<td>See summary for estradiol. Methods similar to those used to measure estradiol can also measure progesterone in blood and urine (Honour 2010; McDonald et al. 2011; Stanczyk and Clarke 2010). Progesterone has also been measured in human saliva (Honour 2010).</td>
</tr>
<tr>
<td>122-34-9</td>
<td>Simazine</td>
<td>Hormone or EDC</td>
<td>The general population may be exposed to simazine via ingestion of contaminated drinking water, ingestion of food, and inhalation of ambient air (NLM 2011). Exposure could also occur through consumption of foods containing residues, though residues were not detected in large-scale surveys of food products in Canada and the USA (IARC 1991a). It is a widely used herbicide to control grasses and weeds in food crops, and it is also used for selective control of algae and submerged weeds in ponds, large aquaria, ornamental fish ponds, and fountains. Prior to 1994 it was approved for use to control algae in hot tubs and swimming pools. Simazine and its degradation products have been detected at low levels in ambient rural and urban air, rainwater, surface and groundwater and, less frequently, in drinking water samples (IARC 1999h). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).</td>
<td>At least one study has measured atrazine and its metabolites in the urine of the general population, and NIOSH includes it in a published method. NIOSH method 8315, exposure to triazine herbicides, measures simazine, atrazine, desethyl atrazine, and desisopropyl atrazine via GC-MS in at least 15 mL urine, LOD 20-47 nmol/L. Chevrier et al. (2011) measured multiple urinary simazine metabolites, detecting simazine or simazine mercapturate in the urine of 8% of pregnant women (n= 579) in Brittany in 2002-2006, while dealkylated and hydroxylated triazine metabolites were detectable in 20% and 40% of samples, respectively. Simazine and atrazine are structurally similar and share many metabolites, so methods for measuring atrazine exposure should be applicable to simazine as well.</td>
</tr>
<tr>
<td>77439-76-0</td>
<td>MX (3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone)</td>
<td>MX</td>
<td>The general population may be exposed via treated (chlorinated) drinking water. MX is a by-product of drinking water disinfection that has been found at nanogram-per-liter levels in drinking water as a result of chlorination or chloramination (IARC 2004). One study identified MX as the primary contributor to genotoxicity of finished drinking water (Brunborg et al. 1991) but other compounds contribute as well. It is listed as a Proposition 65 carcinogen (California OEHHA 2014).</td>
<td>No studies were found using biomarkers to measure exposure to MX. Weisel et al. (1999) and others have used urine trihaloacetic acid levels as markers of exposure to drinking water disinfection by-products.</td>
</tr>
<tr>
<td>75321-20-9</td>
<td>1,3-Dinitropyrene</td>
<td>NitroPAH</td>
<td>1,3-dinitropyrene is found at low concentrations in ambient air and associated with diesel exhaust and air pollution (IARC 1989c). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).</td>
<td>No studies were found using biomarkers of exposure to 1,3-dinitropyrene. Methods for 1-nitropyrene may be adapted.</td>
</tr>
<tr>
<td>42397-65-9</td>
<td>1,8-Dinitropyrene</td>
<td>NitroPAH</td>
<td>The primary route of potential human exposure is inhalation. Detectable levels have been found in respirable particulates from ambient atmospheric samples. Associated with particulate emissions from diesel engines, kerosene heaters, and gas burners. It has also been found at low concentrations in ambient air (IARC 1989c; NTP 2011). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).</td>
<td>No studies were found using biomarkers of exposure to 1,8-dinitropyrene. Methods for 1-nitropyrene may be adapted.</td>
</tr>
<tr>
<td>CAS</td>
<td>Name</td>
<td>Chemical group</td>
<td>Exposure summary</td>
<td>Biomarker summary</td>
</tr>
<tr>
<td>---------</td>
<td>----------------</td>
<td>----------------</td>
<td>-----------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>5522-43-0</td>
<td>1-Nitropyrene</td>
<td>NitroPAH</td>
<td>The general population may be exposed via inhalation of ambient air, ingestion of food and drinking water, and dermal contact. Diesel exhaust is considered the major source of exposure, and 1-nitropyrene is commonly detected in ambient air. 1-nitropyrene has also been detected in the air near coal plants, in fumes from soybean cooking oil, and in dried herbs. (NTP 2011).</td>
<td>Metabolites and adducts of 1-nitropyrene have been measured in the urine and blood of the general population and in workers and experimental volunteers exposed to diesel exhaust. Huyle et al. (2010) and Laumbach et al. (2009) measured the 1-nitropyrene metabolite 1-amino-2-nitropyrene in the urine of volunteers experimentally exposed to diesel exhaust. Zwiner-Baier and Neumann (1999) measured hemoglobin adducts derived from 1-nitropyrene in blood samples from bus garage workers, urban hospital workers, and 14 controls via hydrolysis followed by GC-MS, with LOD 0.01-0.08 pmol/g Hb. (Differences between populations were only evident when multiple NitroPAH adducts were measured). Neumann et al. (1995) used the same method to detect 1-nitropyrene-derived adducts in coke oven workers and controls living in the same area. Toriba (2007), using LC-MS/MS with blue rayon extraction, detected multiple isomers of the 1-nitropyrene metabolite 1-amino-2-nitropyrene in all tested urine samples from the general population; 4 metabolites had mean levels in the hundreds of pmol/mol creatinine. Seidel et al. (2002) measured metabolites of 1-nitropyrene and other PAHs in pre-and post-shift urine samples from salt miners exposed to diesel exhaust, and found large differences in the levels of many metabolites between smoking and non-smoking workers.</td>
</tr>
<tr>
<td>607-57-8</td>
<td>2-Nitrofluorene</td>
<td>NitroPAH</td>
<td>General exposures occur via urban atmospheres, contaminated drinking water supplies and recreational activities at contaminated waterways (NLM 2011). 2-nitrofluorene is found at low concentrations in ambient air and detected in particulate emissions from diesel engines, kerosene heaters, and gas burners. (IARC 1989d). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).</td>
<td>Two studies were found measuring biomarkers of exposure to 2-nitrofluorene in the blood of occupationally exposed workers and controls. Zwiner-Baier and Neumann (1999) measured a hemoglobin adduct derived from 2-nitrofluorene in bus garage workers, urban hospital workers, and 14 controls via hydrolysis followed by GC-MS, with LOD 0.01-0.08 pmol/g Hb. (Differences between populations were only evident when multiple nitroPAH adducts were measured). Neumann et al. (1995) used the same method to detect adducts of a 2-nitrofluorene metabolite in coke oven workers and controls living in the same area. Newer methods for 1-nitropyrene may be adapted.</td>
</tr>
<tr>
<td>5785-92-4</td>
<td>4-Nitropyrene</td>
<td>NitroPAH</td>
<td>The primary route of potential exposure is inhalation. 4-nitropyrene has been measured in diesel exhaust particulate extracts and in particulates derived from coal-burning (NTP 2011). It was found at low concentrations in ambient air in one study (IARC 1989a). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).</td>
<td>No studies were found using biomarkers of exposure to 4-nitropyrene. Newer methods for 1-nitropyrene may be adapted.</td>
</tr>
<tr>
<td>7496-02-8</td>
<td>6-Nitrochrysene</td>
<td>NitroPAH</td>
<td>6-nitrochrysene has been measured in diesel exhaust particulate extracts (NTP 2011), and was found in ambient air at a low concentration in one study (IARC 1989b). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).</td>
<td>Two studies were found measuring biomarkers of exposure to 6-nitrochrysene in the blood of occupationally exposed workers and controls. Zwiner-Baier and Neumann (1999) measured hemoglobin adduct derived from 6-nitrochrysene in bus garage workers, urban hospital workers, and 14 controls via hydrolysis followed by GC-MS, with LOD 0.01-0.08 pmol/g Hb. (Differences between populations were only evident when multiple NitroPAH adducts were measured). Neumann et al. (1995) used the same method to detect adducts of a 6-nitrochrysene metabolite in coke oven workers and controls living in the same area.</td>
</tr>
<tr>
<td>303-47-9</td>
<td>Ochratoxin A</td>
<td>OTA</td>
<td>Exposure can occur through consumption of contaminated grain, nuts, and pork products. It is a naturally occurring mycotoxin with widespread occurrence in food and animal feed (IARC 1993b; NTP 2011). Ochratoxin-contamination of grains is prevalent in some areas of Balkan countries. Ochratoxin exposure has also been demonstrated in a subset of people in the US exposed to mold-contaminated environments or buildings (Hooper et al. 2009). It is a Proposition 65 carcinogen (California OEHHA 2014).</td>
<td>Many studies have used biomarkers in blood and urine to investigate exposure to ochratoxin a (OTA) in general populations, especially in Turkey and other Mediterranean and Balkan countries. Studies have also measured OTA in human breast milk, amniotic fluid, plasma, and biopsies of the lung, liver, and brain. Scott et al. (2005) reviews methods and results of many studies of OTA in blood, urine, and breast milk. Researchers have used ELISA (Erkeköglü et al. 2010), LC-MS/MS (Ritieni et al. 2010), IAAC HPLC-MS (Coronel et al. 2009) and SPE HPLC (Karima et al. 2009) to measure OTA in serum, plasma, and whole blood, and IAC-HPLC-FD (Akkemir et al. 2010) and GC-LC-MS (Ritieni et al. 2010) to measure OTA in urine. Scott et al. (2005) describes various methods of reversed phase LC-FD as the most common for measuring OTA in biological liquids, with typical LODs between 0.01-0.1 ng/mL. Many but not all studies find OTA in the majority of blood, urine, or breast milk samples from the general population (Coronel et al. 2009; Duarte et al. 2010; Erkeköglü et al. 2010; Gürbay et al. 2009; Lino et al. 2008; Scott 2005). Many studies have found regional and seasonal differences in blood and urine levels (Akkemir et al. 2010; Duarte et al. 2010; Erkeköglü et al. 2010; Lino et al. 2008; Scott 2005). At least one study found levels higher in healthy workers in food factories than in controls (Iavicoli et al. 2002). Ritieni et al. (2010) used LC-MS/MS on 21 amniotic fluid samples, detecting OTA in one sample at 4.26 ng/L, despite not detecting it in blood or urine from the same woman. Hooper et al. (2009) used HPLC-Light Alkali Extractability columns and fluorometry (LOD: 2 ppb) on urine, sputum, and biopsies of lung, liver, and brain of patients known to be exposed to toxic molds and control patients. Levels in samples from exposed patients from below the LOD to &gt;10 ppb; there was no detectable OTA in samples from control patients. Kovacs et al. (1995) detected OTA ranging from 0.2-7.3 ng/mL in 38 of 92 colostomy samples via HPLC. Muñoz et al. (2009) used LLE-LC-MS to measure the metabolite ochratoxin alpha (OATalpha) (as well as OTA) in plasma (LOQ 0.1 ng/ml) and urine (LOQ 0.05 ng/ml) from 13 volunteers, and detected OATalpha in all samples at much higher levels than the parent compound. Schau et al. (2008) described detection via HPLC-FLD and LC-MS/MS of many other metabolites.</td>
</tr>
<tr>
<td>56-49-5</td>
<td>3-Methylcholanthrene</td>
<td>PAH</td>
<td>Exposure is associated with the use of 3-MC in biochemical research, and it may also be present in industrial air pollutants, smoke from coal or coke-burners, and in tobacco tar (NLM 2011). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).</td>
<td>No studies were found measuring 3-MC in humans or other mammals. Choudhury et al. (1990) used HPLC to measure 3-MC in catfish plasma. Jones et al. (2009) measured 3-MC in molested snake skin.</td>
</tr>
<tr>
<td>57-97-6</td>
<td>7,12-Dimethylbenz(a)anthracene</td>
<td>PAH</td>
<td>Exposure is likely from laboratory situations through dermal and inhalation routes, given the use of DMBA as a research chemical (NLM 2011). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).</td>
<td>Although no studies have used biomarkers of exposure to measure human exposure to DMBA, two studies have developed methods for its measurement in blood, urine, and other media. Yardim et al. (2010) developed an electrochemical DNA-based biosensor which could detect DMBA in spiked human urine and other media with LOD ~50 ng/L and LLOQ ~500 ng/L. Yardim et al. (2012) used HPLC with diode array detection for the determination of DMBA in serum, urine, and kidney of rats fed DMBA.</td>
</tr>
<tr>
<td>CAS</td>
<td>Name</td>
<td>Chemical group</td>
<td>Exposure summary</td>
<td>Biomarker summary</td>
</tr>
<tr>
<td>-----</td>
<td>------</td>
<td>----------------</td>
<td>------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>50-32-8</td>
<td>Benzo[a]pyrene</td>
<td>PAH</td>
<td>Exposure occurs primarily through the smoking of tobacco, inhalation of polluted air, and ingestion of food and water</td>
<td>Many studies have investigated markers of benzo[a]pyrene (BaP) in blood in general populations, and in urine from occupationally exposed populations. Methods have also been developed for measuring BaP or markers in breast milk, placental tissue, aborted fetal tissue, follicular fluid, semen, and lung tissue. The most commonly measured biomarkers of BaP exposure are DNA and protein adducts measured in blood. BaP-specific adducts, including BPDE-DNA and BPDE-protein (albumin and hemoglobin) adducts, are typically measured by HPLC-FD or GC-MS (Boysen and Hecht 2003; Kääferlein et al. 2010). Nonspecific &quot;bulky&quot; or &quot;BaP-like&quot; DNA adducts have been detected by 32P-post-labeling and immunoassays, which are more sensitive but typically cannot differentiate between PAHs (Boysen and Hecht 2003; Kääferlein et al. 2010). Epidemiologists have used immunoassays to measure nonspecific PAH-DNA adducts in cancer studies (Gammon et al. 2002; Rundle et al. 2002). Researchers have had limited success differentiating between exposed and unexposed populations through use of BaP-specific adducts (Boysen and Hecht 2003; Kääferlein et al. 2010). Singh et al. (2008) used HPLC-FPUV to detect BaP itself in blood from children in India, finding a median level of 4 ppb. Although at least one study using HSi-SPME (Waidyanatha et al. 2003) failed to detect BaP itself in urine from exposed coke plant workers, multiple studies have detected 3-OHBP in urine from occupationally exposed workers using HPLC (Szansizsö and Ungváry 2001) or LC-EC-MS (Rossella et al. 2009). Szansizsö and Ungváry (2001) found higher levels of 3-OHBP in urine from smokers than non-smokers, but found no difference between healthcare workers, policemen, and asphalt production workers. BaP exposure has been measured in many other biological media as well. Madhavan and Naiku (1995) found &quot;relatively high concentrations&quot; of BaP in umbilical cord blood and breast milk collected from women in India. Toriba et al. (2003) developed an HPLC-FD method to measure BaP and other PAHs in human hair. Singh et al. (2008) found BaP levels measured by HPLC-FD elevated, but not significantly, in 20 placental tissues from preterm pregnancies, compared to 31 from full-term pregnancies. BaP has also been measured in lung samples collected during surgery (Bartsch et al. 1993) or autopsy (Lodovici et al. 1998); in both cases, levels of BaP in lung tissue were correlated with levels of BaP derived DNA adducts. Additional studies have measured BaP or its metabolites or adducts in aborted tissue (Wu et al. 2010), follicular fluid, in which levels were higher in smokers than non-smokers (Neal at al. 2008), and semen (Zenes et al. 1999). For reviews, see Kääferlein et al. (2010), Benford et al. (2010), Dying et al. (2008), and Boysen and Hecht (2003).</td>
</tr>
<tr>
<td>53-70-3</td>
<td>Dibenzo[def,p]chrysene</td>
<td>PAH</td>
<td>Exposure occurs primarily through the smoking of tobacco, inhalation of polluted air, and ingestion of food and water</td>
<td>General population, occupational, and method development studies have measured exposure to dibenzo[def,p]chrysene (DB(a,l)P) in blood samples, placenta, hair, lung tissue, and nasal cells. Peluso (2004), studying smokers, measured specific DNA adducts for DB(a,l)P in lymphocytes and nasal and bronchial mucosa, finding the highest levels in nasal mucosa. 10^6 relative adduct levels (mean ± SD) were 1.10 ± 0.66 in nasal samples, 0.82 ± 0.36 in lung samples and 0.54 ± 0.39 in lymphocytes. Gladen et al. (2000) measured DB(a,l)P and 5 other PAHs in placenta from 200 women from 2 cities in Ukraine, and found a median of 0.73 ng/g dry weight. DB(a,l)P levels were higher in the larger city, and higher in placenat from mothers with higher BMIs. Lodovici et al. (1998) measured dibenzo[a,l]anthracene in lung tissue from autopsied smokers (0.18 ± 0.17 ng/g dry weight, mean ± SD), ex-smokers (0.7 ± 0.03), and non-smokers (0.046 ± 0.025). Toriba et al. (2003) developed a method for analyzing DB(a,l)P and other PAHs in human hair with HPLC and fluorescence detection, finding DB(a,l)P in some but not all hair samples.</td>
</tr>
<tr>
<td>191-30-0</td>
<td>Dibenzo[def,p]chrysene</td>
<td>PAH</td>
<td>Exposure occurs mainly through the smoking of tobacco, inhalation of polluted air, and ingestion of food and water</td>
<td>One study of smokers measured exposure to dibenzo[def,p]chrysene (also known as dibenzo[a,l]pyrene or DB(a,l)P) in human blood, nasal cells, and lung cells. Another study used mouse skin: Peluso (2004), studying smokers, measured specific DNA adducts for DB(a,l)P in lymphocytes, finding the highest levels in nasal mucosa. Mean 10^6 relative adduct levels were 1.10 ± 0.66 in nasal samples, 0.82 ± 0.36 in lung samples and 0.54 ± 0.39 in lymphocytes. Roberts et al. (2001) describe using HPLC-fluorescence line-narrowing spectroscopy to measure and analyze DNA adducts in mouse skin that had been exposed to DB(a,l)P.</td>
</tr>
<tr>
<td>335-67-1</td>
<td>Perfluorooctanoic acid</td>
<td>PFOA</td>
<td>PFOA is widely detected in blood samples in the US. It is used in non-stick and stain-resistant coatings on rugs, furniture, clothes, cookware, fire-fighting applications, cosmetics, lubricants, paints, and adhesives. Former use in insecticide and herbicide formulations resulted in its direct release to the environment (NLM 2011). It is an EPA Action Plan Chemical, with exposures from drinking water, aquatic organisms, soil, and consumer products (US EPA 2013b).</td>
<td>NHANES and others have measured PFOA in blood from the general population, as well as from groups exposed occupationally or through industrial contamination. PFOA has also been measured in human milk samples and human thyroid tissue. NHANES uses online SPE-HPLC-MS/MS for the measurement of PFOA and 17 other perfluorinated chemicals in 100 µL of serum, with LOD 0.1 ng/mL and LLOQ 0.3 ng/mL (Bartelt et al. 2010; Calafat et al. 2007a; Kuklenyik et al. 2005). NHANES has used off-line SPE in the past, with similar results (Calafat et al. 2007b). Sundstrom et al. (2011) measured PFOA at 74 µg/g in pooled Swedish human milk samples from 2008, with LOD in the low pg/mL. Others have also measured PFOA and other PFCs in human milk samples, usually with higher LODs (Fromme et al. 2010; Lorca et al. 2010; Roossens et al. 2010). Pirali et al. (2009) measured PFOA in thyroid tissues from 28 patients undergoing surgery for thyroid diseases, detecting PFOA at between 0.4-4.6 ng/g in all, but at lower levels than in patients’ serum. Lau (2007), Houde (2006), and Harada and Koizumi et al. (2009) review other biomonitoring studies of PFOA and other PFCs.</td>
</tr>
<tr>
<td>121-66-4</td>
<td>2-Amino-5-nitroimidazole</td>
<td>Pharmaceutical</td>
<td>The general population may be exposed through residues of 2-amino-5-nitroimidazole in food products. It is a synthetic veterinary</td>
<td>No studies were found using biomarkers of exposure to 2-amino-5-nitroimidazole.</td>
</tr>
<tr>
<td>23214-92-8</td>
<td>Adriamycin</td>
<td>Pharmaceutical</td>
<td>Adriamycin is a chemotherapeutic drug used to treat a variety of cancers. National Occupational Exposure Survey estimated that 17,132 health-services workers were potentially exposed from 1981-1983. It can be found unchanged in human waste (NTP 2011).</td>
<td>A few studies have described methods for measuring adriamycin in urine. Sottani et al. (2008) measured adriamycin in urine by rp-HPLC-ESI-MS/MS with LLOQ 0.3 µg/L. Sottani et al. (2004) measured adriamycin in urine by HPLC/MS/MS with LLOQ 0.1 µg/L.</td>
</tr>
<tr>
<td>CAS</td>
<td>Name</td>
<td>Chemical group</td>
<td>Exposure summary</td>
<td>Biomarker summary</td>
</tr>
<tr>
<td>---------</td>
<td>-----------------------</td>
<td>------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>50-18-0</td>
<td>Cyclophosphamide</td>
<td>Pharmaceutical</td>
<td>Cyclophosphamide has been widely used since the early 1950s in the treatment of malignant lymphoma, multiple myeloma, and cancers of the breast, ovary, and lung. It has also been used in the treatment of certain chronic diseases, such as rheumatoid arthritis and chronic glomerulonephritis and other nonmalignant diseases (ARC 1981). It is listed as a Proposition 65 carcinogen and development toxicant (California OEHHA 2014). There have been many studies of cyclophosphamide (CP) levels in urine of healthcare workers and a few of CP levels in urine and blood of chemotherapy patients. Fransman et al. (2007), reviewing three studies in the Netherlands, reports that between 1997 and 2000 the proportion of samples with measurable CP levels went down fourfold, and the median concentration in samples with detectable CP went down threefold. Fransman et al. (2002) or very few (Favier et al. 2003) subjects’ urine, and some finding CP in urine from over half of subjects (Minoia et al. 1998; Sessini et al. 1997; Sugiraju et al. 2011). In plasma, LC-MS/MS has been used with LOD 0.02 ng/ml (Hedner et al. 2008). B’Hymer and Kociba (2009) used LC-MS/MS to detect cyclophosphamide and its metabolite 4-ketocyclophosphamide in urine, with LODs 1 ng/ml for the metabolite and 0.1 ng/ml for CP. Villarini et al. (2011) and Moretti et al. (2011) describe a study design using urinary cyclophosphamide as a biomarker of exposure to antineoplastic drugs, to be compared with biomarkers of DNA damage.</td>
<td></td>
</tr>
<tr>
<td>4342-03-4</td>
<td>Dacarbazine</td>
<td>Pharmaceutical</td>
<td>Dacarbazine is used in cancer therapy (NTP 2011) It is listed as a Proposition 65 carcinogen (California OEHHA 2014). Methods have been developed to measure furosemide (FD) concentrations in blood and urine from patients or volunteers receiving FD. Reeuwijk et al. (1992) used LLE-HPLC with florescence detection, with LOD 0.3 ng/ml in plasma from volunteers receiving FD and amiloride. Margalho et al. (2005) obtained a DL of 10 ng/ml in spiked whole blood with SPE-GC-EI-MS, Saugy et al. (1991) measured FD in serum and urine from experimentally dosed volunteers via HPLC-florescence. Zhang et al. (2008) obtained a DL of 0.5 ng/ml in urine using HFLPF(2014), and HFLPC-UV. No studies were found measuring biomarkers of exposure to dacarbazine.</td>
<td></td>
</tr>
<tr>
<td>54-31-9</td>
<td>Furosemide</td>
<td>Pharmaceutical</td>
<td>Furosemide is a potent, short-acting sulfonamide diuretic chemically similar to the thiazides, commonly used as a medical treatment in a variety of situations ranging from the control of hypertension to the reduction of edema of cardiac, hepatic, or renal origin. It is particularly useful in the management of acute pulmonary edema and may be used in premature infants to promote the diuresis that usually follows birth. The number of prescriptions for furosemide in the United States increased from 16 million in 1973 to 23 million in 1981 (NTP 1989). A few studies have measured furosemide in plasma or other fluids from patients or volunteers who had been administered griseofulvin, and more describe pharmacokinetic studies. Mistl et al. (2007) described ESI-LCM SMS to measure griseofulvin, with LLOG 20 ng/ml, in plasma from six healthy subjects after they ingested 000 mg griseofulvin as part of a bioequivalence study. Pacifile (2006), reviewing transpantational transfer of multiple antibiotics, reports that griseofulvin has been measured in cord plasma as well as maternal plasma. Additional pharmacokinetic studies have measured griseofulvin in human intestinal mucus (Gramatte 1994), and griseofulvin and its metabolites varied fluids from experimental animals (Ahmed and About-Einia 2007; Fujikwa et al. 2008; Poulain-Tremeau et al. 2008). Many studies have measured griseofulvin in intestinal mucus as part of an availability study.</td>
<td></td>
</tr>
<tr>
<td>126-07-8</td>
<td>Griseofulvin</td>
<td>Pharmaceutical</td>
<td>Griseofulvin is an anti-fungal used to treat infections of skin, hair, and nails (ARC 2001c; NLM 2011). It is listed as a Proposition 65 carcinogen (California OEHHA 2014). A few studies have measured griseofulvin in plasma or other fluids from patients or volunteers who had been administered griseofulvin, and more describe pharmacokinetic studies. Mistl et al. (2007) described ESI-LCM SMS to measure griseofulvin, with LLOG 20 ng/ml, in plasma from six healthy subjects after they ingested 500 mg griseofulvin as part of a bioequivalence study. Pacifile (2006), reviewing transpalatal transfer of multiple antibiotics, reports that griseofulvin has been measured in cord plasma as well as maternal plasma. Additional pharmacokinetic studies have measured griseofulvin in human intestinal mucus (Gramatte 1994), and griseofulvin and its metabolites varied fluids from experimental animals (Ahmed and About-Einia 2007; Fujikwa et al. 2008; Poulain-Tremeau et al. 2008). Many studies have measured griseofulvin in intestinal mucus as part of an availability study.</td>
<td></td>
</tr>
<tr>
<td>53-86-1</td>
<td>Indomethacin</td>
<td>Pharmaceutical</td>
<td>Indomethacin is a non-steroidal anti-inflammatory agent, used to treat inflammatory and non-inflammatory diseases (NLM 2011, 2014). Many studies have measured indomethacin in human blood and urine for pharmacokinetics studies or patient monitoring. Methods to measure indomethacin in plasma and serum include LC (Al Za‘abi et al. 2006; Miksa et al. 2005; Wang et al. 2013), &quot;micellar electrokinetic chromatography-UV detection&quot; (Lin et al. 2006), and GC-MS (Thomas et al. 2010). Al Za‘abi et al. (2006) describe HPLC with LLOG 25 ng/mL in plasma from neonates, and Mannila et al. (2007) report levels as low as 0.3 mg/ml in mouse tissue, but do not provide methods information in the abstract. In urine, LC-based methods are the most common (Cruz-Vera et al. 2009; Michail and Moneeb 2011; Riano et al. 2012; Wang et al. 2013), although Molina-Garcia et al. (2010) described &quot;sequential injection analysis and opto sensing&quot; with LOD 0.15 ng/ml, and LLOG of 0.5 ng/ml in mouse tissue, making it more sensitive than most LC methods. Mannila et al. (2007) measured indomethacin in cerebrospinal fluid (CSF) and plasma from in children who had administered IV indomethacin, finding plasma levels always at least 100 times CSF levels.</td>
<td></td>
</tr>
<tr>
<td>54-85-3</td>
<td>Isoniazid</td>
<td>Pharmaceutical</td>
<td>Isoniazid is an anti-fermentation agent, used to treat tuberculosis. The National Occupational Exposure Survey estimated that 2,924 workers (1,480 female) were potentially exposed to isoniazid in the US from 1981-1983 (NLM 2011). Isoniazid has been measured in blood, urine, breastmilk, and cerebrospinal fluid from patients prescribed isoniazid for clinical monitoring and pharmacokinetics studies. However, Pelosi et al. (2002) reported that limits of detection were generally only sufficient to measure isoniazid within a few hours of dosing. HPLC appears to be the most common method for measurement in plasma and serum (Ge et al. 2008; Huang et al. 2009; Xu et al. 2013; Zhao et al. 2011; Zhu et al. 2010), with detection and quantification limits around 0.2-0.5 µg/mL (Huang et al. 2009; Zhu et al. 2011). Other methods used in blood include &quot;cation selective exhaustive injection sweeping micellar electrokinetic chromatography&quot; (Tsai et al. 2011). HPLC and other methods have been used to measure isoniazid and metabolites in urine (Bergamini et al. 2010; Espinosa-Mansilla et al. 2002; F Li et al. 2011; Nicolau et al. 2012; Zhou et al. 2009). Isoniazid has also been measured in cerebrospinal fluid (Donald 2010; Sullivan and Abdel-Rahman 2013) and breastmilk (N Singh et al. 2008).</td>
<td></td>
</tr>
<tr>
<td>443-48-1</td>
<td>Metronidazole</td>
<td>Pharmaceutical</td>
<td>Metronidazole is an anti-fermentation agent administered orally, topically, or through injection (NLM 2011). Used in pet fish care products (NLM 2013). It is listed as a Proposition 65 carcinogen (California OEHHA 2014). Many studies have measured metronidazole in the blood, urine, and other bodily fluids of patients and volunteers dosed with metronidazole. De Freitas Silva (2012), Cohen-Wolkowiez (2011), Suyagh (2011), and do Nascimento (2005) used various LC methods to measure metronidazole in plasma. Salem (2012) used NMR to measure metronidazole in plasma and urine, with LLOG 0.28 ng/mL. Jafari (2009) used &quot;IM mobility spectrometry&quot; to measure metronidazole in serum, with LLOQ 2.3 ng/mL. Liu et al. (2013) used a graphene-based electrode material to measure metronidazole in urine (and lake water), with LOD 2.3 µg/mL and LLOG of 10 µg/mL. Sun et al. (2012) used HPLC with photo diode array detector to measure metronidazole in urine with LOD 0.1 µg/mL. Salem et al. (2008) used NMR to measure metronidazole in urine as well as saliva and gingival crevicular fluid.</td>
<td></td>
</tr>
<tr>
<td>139-94-6</td>
<td>Nitrazide</td>
<td>Pharmaceutical</td>
<td>Exposure may result from the use of nitrazide in veterinary medicine (ARC 1983a). It may persist in the tissues and eggs of treated poultry (NTP 1979). No studies were found using biomarkers to measure exposure to nitrazide.</td>
<td></td>
</tr>
<tr>
<td>CAS</td>
<td>Name</td>
<td>Chemical group</td>
<td>Exposure summary</td>
<td>Biomarker summary</td>
</tr>
<tr>
<td>------</td>
<td>--------------------------</td>
<td>----------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>67-20-9</td>
<td>Nitrofurantoin</td>
<td>Pharmaceutical</td>
<td>Nitrofurantoin has been used since 1972 in treatment of urinary tract infection (IARC 1990). It is a Proposition 65 male toxicant (California OEHHA 2014).</td>
<td>Some studies described testing of human urine, plasma, and breast milk after administration of nitrofurantoin. Muth et al. (1996) described LLE-HPLC to detect nitrofurantoin in plasma and urine, with LLOQ 0.01 µg/mL in plasma and 0.38 µg/mL in urine. Aufrere et al. (1977) described HPLC in 0.2 mL samples of plasma and urine, with LLOQ 0.02 µg/mL in both media. Arancibia et al. (2003) used SPE-HPLC to detect nitrofurantoin and a radical anion metabolite in urine with detection limits of 12.1 µM and 0.9 µM, respectively. Xu et al. (2009) used an immunochromatographic assay to detect the nitrofurantoin metabolite 1-aminoxyhydrin in urine with a detection limit of 10 ng/mL. Pons et al. (1990) used HPLC to measure nitrofurantoin levels in breast milk and blood of women taking nitrofurantoin, quantifying levels in the 10s of µg in human milk (Pons et al. 1990).</td>
</tr>
<tr>
<td>59-87-0</td>
<td>Nitrofurazone</td>
<td>Pharmaceutical</td>
<td>Nitrofurazone is a synthetic furan derivative active against a broad spectrum of bacteria, and has been used widely in veterinary and human medicine as well as (NTP 1988) pet care products, specifically fish care (NLM 2013). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).</td>
<td>No occupational or general population studies were found for nitrofurazone, but method development studies described testing of human urine and plasma. Du et al. (2007) used flow induction chemiluminescence, with LOD 20 ng/mL and LLOQ 100 ng/mL in both plasma and urine. Aufrere et al. (1979) used LLE-HPLC with LLOQ 200 ng/mL in plasma and urine, to measure nitrofurazone and stated that the method was also applicable to nitrofurazone.</td>
</tr>
<tr>
<td>62-44-2</td>
<td>Phenacetin</td>
<td>Pharmaceutical</td>
<td>Until 1983, phenacetin was used in over-the-counter remedies for pain and fever; however, it no longer is used in drug products in the United States. It was once used as a stabilizer for hydrogen peroxide in hair-bleaching preparations (NTP 2011). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).</td>
<td>Some older methods-development and dosing experiment studies have investigated possible biomarkers of phenacetin. Gotelli et al. (1987) described HPLC on 0.1 mL plasma samples, obtaining LLOQ 0.5 µg/mL for phenacetin. Garland et al. (1977) used GLC-chemical oxidation MS on 1 mL plasma samples, obtaining a &quot;sensitivity limit&quot; of 1 ng/mL. Murray and Bobbis (1991) used GC-MS to quantify phenacetin and its metabolite paracetamol (Tylenol) in plasma, detecting amounts equivalent to 1 pg of parent compound. Davies et al. (1984) used TLC-MS with multiple-peak monitoring for paracetamol in urine. Dittman and Renner (1977) used silica-gel TLC to measure the metabolite 4-acetaminophenoxyacetic acid in rat, dog and human urine, detecting 0.04% of a 200 mg/kg dose.</td>
</tr>
<tr>
<td>50-55-5</td>
<td>Reserpine</td>
<td>Pharmaceutical</td>
<td>Reserpine is an anti-hypertensive, recently not widely used. The National Occupational Exposure Survey estimated that 5611 workers (2414 female) were potentially exposed to reserpine in the US from 1981-1983 (NLM 2011).</td>
<td>A few studies have described methods for measurement of reserpine in human blood and urine. Tas et al. (1986) used LC-MS with a detection limit around 10 pg to measure reserpine in human serum, for use in testing poisoning victims for overdoses. Owen et al. (1985) described in HPLC method for the analysis of reserpine and related compounds in blood, with detection limits around 50 pg/mL. Li et al. (2011) used HPLC to measure reserpine in human urine with LOD 7.1 ng/mL and LOD of 23.6 ng/mL.</td>
</tr>
<tr>
<td>52-24-4</td>
<td>Thiolepa</td>
<td>Pharmaceutical</td>
<td>ThioTEPA is used in cancer therapy (NTP 2011). No studies were found measuring thiotePA in the general public or in occupational settings, but methods have been developed for blood and urine. Van Maanen et al. (1997) obtained LLOQ 1 ng/mL in 100 ml samples of plasma and urine with capillary GC with a thermionic N- P detector. LC-MS/MS was validated over 5-2500 ng/mL for the metabolite TEPA (and thioTEPA) in 100 blood samples (de Jonge et al. 2004). In urine, GC with selective N-P detection, was linear from 25-5000 ng/mL for TEPA, and from 25-2500 ng/mL for the metabolite monochloroTEPA (van Maanen et al. 2000). Also in urine, LC-MS with direct sample injection with sulphadiazine as internal standard was linear from 1-25 µg/mL for the metabolite thioTEPA-mercapto (van Maanen and Bejein 1999).</td>
<td></td>
</tr>
<tr>
<td>100-42-5</td>
<td>Styrene</td>
<td>Styrene</td>
<td>Exposure to the general population occurs at levels of micrograms per day due mainly to inhalation of ambient air and cigarette smoke and intake of food that has been in contact with poly(styrene). Styrene is present in a number of consumer products including carpets, adhesives, hobby and craft supplies and glues, and home maintenance products (IARC 2002; NLM 2013; NTP 2011). It is a TSCA Work Plan Chemical, identified as having a high likelihood of exposure. It is present in drinking water, surface water, ambient air, groundwater, and soil; moderate releases to the environment have been reported (US EPA 2012). It is on the Canadian Priority Substances List, with indoor air exposures from cigarette smoke, and low environmental exposures (Health Canada 1993).</td>
<td>NHANES and others have measured styrene and its metabolites and adducts in blood samples from the general population and urine from general population and occupationally exposed groups, and a few studies have measured styrene in human saliva and breast milk. In 2001-2002 and 2003-2004, NHANES used HS-SPME-GC-MS, LOD 0.03 ng/mL on 3 mL (minimum) to 10 mL (optimal) whole blood and detected styrene in less than half of the general population (CDC 2012b). It has been measured in urine, breast milk and saliva. Atkinson et al. (2010) used HPLC-MS/MS to detect styrene metabolites in human urine and saliva, with LLOQ 1 µg/day for phenylacetonitrile, 1 µg/day for phenylacetylglycine and 1 µg/day for phenylacetylglycolic acid in urine and saliva. Blount et al. (2010) used SPE headspace GC selected ion monitoring MS on 3 ml breast milk from 12 women, with a median level of 125 ng/ml in breast milk.</td>
</tr>
<tr>
<td>CAS</td>
<td>Name</td>
<td>Chemical group</td>
<td>Exposure summary</td>
<td>Biomarker summary</td>
</tr>
<tr>
<td>-------</td>
<td>--------------------</td>
<td>----------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>123-91-1</td>
<td>1,4-Dioxane</td>
<td>Miscellaneous</td>
<td>Exposure of the general population to 1,4-dioxane could possibly occur from contact with products containing residues of the compound. According to the Consumer Product Safety Commission (CPSC), consumers may possibly be exposed to residual levels of 1,4-dioxane formed during the manufacture of detergents, shampoos, surfactants, and certain pharmaceuticals. It is also found in home and auto-use adhesives (NLM 2013). CPSC reported that the presence of 1,4-dioxane, even as a trace contaminant, is cause for concern and the Commission monitors its use in consumer products. Residues may be present in food packaged in 1,4-dioxane-containing materials or on food crops treated with 1,4-dioxane-containing pesticides (NTP 2011). It is detected in ambient air (IARC 1999c) and monitoring data also indicate that the general population may also be exposed to 1,4-dioxane via ingestion of drinking water (NLM 2004). It is a TSCA Work Plan Chemical, identified as having a high likelihood of exposure. High releases to the environment have been reported (US EPA 2012). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).</td>
<td>No studies were found using biomarkers of exposure to 1,4-dioxane.</td>
</tr>
<tr>
<td>532-27-4</td>
<td>2-Chloroacetophenone</td>
<td>Miscellaneous</td>
<td>The use of &quot;Chemical Mace&quot; to disable attackers causes direct exposure to 2-chloroacetophenone through eye and skin contact and inhalation (NLM 2011).</td>
<td>No studies were found using biomarkers of exposure to 2-chloroacetophenone.</td>
</tr>
<tr>
<td>75-55-8</td>
<td>2-Methylaziridine</td>
<td>Miscellaneous</td>
<td>Potential consumer exposure could occur as a result of handling products coated with 2-methylaziridine or its derivatives; however, there are few ongoing consumer uses of this compound (NTP 2011). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).</td>
<td>No studies were found using biomarkers for 2-methylaziridine</td>
</tr>
<tr>
<td>107-13-1</td>
<td>Acrylonitrile</td>
<td>Miscellaneous</td>
<td>The general population may be exposed through consumer product usage such as acrylic carpeting, rubber, food containers, and toys or by ingestion of contaminated foods. Foods most likely to contain measurable acrylonitrile are high-fat or highly acidic items, such as luncheon meat, peanut butter, margarine, vegetable oil, or fruit juice. Exposure is thought to be low because there is little migration of the monomer into such products (NTP 2011). Acrylonitrile has been measured in the vapor phase of mainstream tobacco smoke and has been detected rarely and at low levels in ambient air and water (IARC 1999b; NTP 2011). It is found in household spackling and caulk (NLM 2013). It is a TSCA Work Plan Chemical, identified as having a high likelihood of exposure. It is present in indoor environments, surface water, ambient air, and groundwater; high releases to the environment have been reported (US EPA 2012). It is on the Canadian Priority Substances List, with exposure from food packaged in acrylonitrile-based plastics (Environment Canada 2011). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).</td>
<td>Many studies have measured acrylonitrile, its metabolites, or its adducts in the blood and urine of smokers and non-smokers. NHANES has measured 2-hydroxyethyl mercapturic acid (HEMA), a common metabolite of 1,2-dibromoethane, vinyl chloride, acrylonitrile, and ethylene oxide, in urine by isotope dilution and HPLC-MS/MS, detecting it in 71% of samples, with higher levels in smokers (Calafat et al. 1999). CDC is planning to add UPLC-ES-MS/MS testing for HEMA (LOD 0.6 ng/mL) and for the AN-specific mercapturic acid N-acetyl-S-(2-cyanoethyl)-L-cysteine (CYMA; LOD 0.5 ng/mL) to future NHANES reports (Alwis et al. 2012). A CDC pilot study found that CYMA levels were significantly different in smokers and non-smokers (Alwis et al. 2012), consistent with many other reports of higher levels of CYMA (Minet et al. 2011; Schertgen et al. 2009) and acrylonitrile (Perbellini et al. 2003a) itself in urine from smokers compared to non-smokers. In blood, acrylonitrile-derived hemoglobin adduct levels are well correlated with self-reported smoking levels (Kütting et al. 2008; Schettgen et al. 2002). Though many studies detected the adduct in both non-smokers and smokers, Schettgen et al. (2010) using isotope dilution GC NCI MS/MS, with LOD 0.5 pmol/g globin did not detect it in the majority of blood samples from non-smokers who were not exposed to secondhand smoke at home, and did detect it in the majority of samples from those exposed. Similarly, Schettgen (2004) detected the adduct in maternal and umbilical cord blood from one smoker, but not from any of the 10 non-smokers tested, or in the umbilical cord blood of their recently delivered infants. Schettgen (2009) and Fennell (2006) found that genotype of glutathione transferase gene had little effect on adduct levels.</td>
</tr>
</tbody>
</table>
### CAS Number | Name | Chemical group | Exposure summary | Biomarker summary |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>368-53-7</td>
<td>AF-2 (2-(2-furyl)-3-(5-nitro-2-furyl) acrylamide)</td>
<td>Miscellaneous</td>
<td>No studies were found using biomarkers to measure exposure to AF-2 2-(2-furyl)-3-(5-nitro-2-furyl) acrylamide.</td>
<td></td>
</tr>
<tr>
<td>NA</td>
<td>Bracken fern (and its extracted chemicals)</td>
<td>Miscellaneous</td>
<td>No studies were found using biomarkers to measure exposure to bracken fern, nor to plaatgoside, the major carcinogen it produces.</td>
<td></td>
</tr>
<tr>
<td>2425-06-1</td>
<td>Captan</td>
<td>Miscellaneous</td>
<td>The fungicide captan is not currently registered for use as a pesticide in the US (NTP 2011). It was widely used after 1961 for the control of fungal diseases in fruits, vegetables, some other plants, and lumber (IARC 1991b; NLM 2011). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).</td>
<td>Multiple studies have measured tetrahydrothalidomide (THPI), a common metabolite of captan and the related pesticide captan, in blood and urine of farm workers, intentionally dosed volunteers, and populations with high use of pesticides in the home. Most of these studies focus on assessing captan exposure and toxicokinetics. Whyatt et al. (2003) used SPE-isolation dilution GC-high resolution MS with LOD 1 µg/L to measure THPI in plasma from 230 African-American and Dominican mothers from northern Manhattan and their newborn infants, detecting THPI in 50% of maternal samples. Berthet et al. (2011) describes LC-atmospheric pressure chemical ionization-MS/MS to measure THPI and thalidomide in blood (LOD 0.58 µg/L) and urine (LOD 1.47 µg/L), and Berthet (2012a; 2012b) measured toxicokinetics of captan in urine and plasma after voluntary dermal and oral exposure, finding half-lives ranging from 16 to 27 hours depending on route of exposure and matrix. McCauley et al. (2008) found significant differences in urinary THPI between 134 workers in Oregon berry fields (mean 0.14 µg/mL) and control non-agricultural workers (mean 0.078 µg/mL). Hines et al. (2008) found a difference in urinary THPI levels between captan applicators using different methods. De Cock et al. (1995) found THPI levels in urine of fruit growers was strongly related to captan exposure estimates from skin pads on ankles and neck, and lower in growers using more protective measures.</td>
</tr>
<tr>
<td>126-99-8</td>
<td>Chloroprene</td>
<td>Miscellaneous</td>
<td>Although few data are available on environmental occurrence, general population exposures to chloroprene are expected to be very low or negligible (IARC 1991c). It is used almost exclusively for the production of neoprene elastomers and latexes, a synthetic rubber used in the production of automotive and mechanical rubber goods, adhesives, caulks, flame-resistant cushioning, construction goods, fabric coatings, sealants for dams or locks in waterways, roof coatings, fiber binding, and footwear (NTP 2011). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).</td>
<td>One recent study detected biomarkers of exposure to 2-chloroprene in urine from an occupationally exposed population. Biomarkers have also been measured in mouse blood. Eckert et al. (2013) measured elevated levels of 3-chloro-2-hydroxy-3-butyl mercapturic acid (CI-MA-III), 3,4-dihydroxybutyl mercapturic acid (DHBMA), and 4-hydroxy-3-oxobutyl mercapturic acid (HOBMA) in the urine of 14 workers occupationally exposed to 2-chloroprene compared to 30 controls. Eckert et al. (2012) detailed their LC-MS/MS method to measure urinary CI-MA-III, DHBMA, and HOBMA, along with other mercapturic acids, with detection limits between 1.4 and 4.20 µg/L. Hurst and All (2007) describe a method, used with mouse erythrocytes, to measure hemoglobin adducts with 1-chloroethenoylamine, a chloroprene metabolite, using headspace analysis with capillary GC-MS.</td>
</tr>
<tr>
<td>1420-04-8</td>
<td>Clonitralid</td>
<td>Miscellaneous</td>
<td>The major route of population exposure to clonitralid is presumably dermal contact with or ingestion of treated water or ingestion of contaminated fish. It is directly applied to control sea lamprey larvae in tributaries to the Great Lakes and widely applied to control water snails (NTP 1978c).</td>
<td>No studies were found using biomarkers to measure human exposure to clonitralid, although a method has been developed to measure it in nonhuman biological samples. Caldwell et al. (2009) used reverse phase LC-MS/MS with solvent extraction with 1% acetic acid in acetonitrile and clean-up via mixed-mode anion-exchange SPE to measure clonitralid and other anthelmintics in bovine kidney tissue.</td>
</tr>
<tr>
<td>62-73-7</td>
<td>Dichlorvos</td>
<td>Miscellaneous</td>
<td>Household uses of dichlorvos represent the main sources of human exposure (IARC 1991c). The general population may be exposed via inhalation of air and dermal contact when no-pest strips, sprays or flea collars contain this insecticide. Exposure could also result from ingestion of food which has been prepared in rooms where dichlorvos is used for insect control (NLM 2011). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).</td>
<td>NHANES and others have measured urinary dimethyl phosphate (DMP), a metabolite of dichlorvos and many other organophosphate pesticides, in the general population and in exposed subjects. DMP has also been measured in hair samples from unexposed and exposed subjects. More specific biomarkers have been measured in the urine and blood of poisoning victims. Since 1999, NHANES has used isoelution GC-MS to measure DMP in urine, with LOD 0.5 µg/L, estimating detectable levels in between 25% and 50% of the population (CDC 2009). Multiple studies have found higher levels of urinary DMP and other OP metabolites in farmworkers and their children (Coronado et al. 2011; Lee et al. 2007) than in nonfarm workers and their children. Urinary DMP levels are also higher in people living closer to farmland (Bradman et al. 2011; Coronado et al. 2011). Tsatsakis et al. (2010) measured DMP and three other dialkyl phosphates in hair samples from the general population and from occupationally exposed subjects via methanolic extraction, derivatization with pentfluorobenzyl bromide, and GC-MS, detecting large and significant differences between the groups (DMP was detectable in 63% of general population hair samples and 100% of occupationally exposed samples). Biomonitoring of dichlorvos-specific biomarkers has focused on cases of acute poisoning (often suicide attempts), in which dichlorvos or its metabolites have been detected in hair, blood, and urine (Abe et al. 2008; Heinig et al. 2000; Inoue et al. 2007; Bin Li et al. 2010; B. Li et al. 2010; Musshoff et al. 2002; Takayasu et al. 2001).</td>
</tr>
<tr>
<td>CAS</td>
<td>Name</td>
<td>Chemical group</td>
<td>Exposure summary</td>
<td>Biomarker summary</td>
</tr>
<tr>
<td>-------</td>
<td>-----------------------</td>
<td>----------------</td>
<td>------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>1694-09-3</td>
<td>FD&amp;C Violet no. 1</td>
<td>Miscellaneous</td>
<td>FD&amp;C Violet no.1 was used as a dye for wool, leather, nylon, andodized aluminum, inks, paper, biological stain, wood stain, color additive for foods, drugs, and cosmetics until 1973 (NLM 2011). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).</td>
<td>No studies were found using biomarkers to measure exposure to FD&amp;C Violet no.1.</td>
</tr>
<tr>
<td>51630-58-1</td>
<td>Fenvalerate</td>
<td>Miscellaneous</td>
<td>Use as a contact insecticide releases fenvalerate directly to the environment in sprays, dusts, concentrates and other routes of application (NLM 2011). It is detected in consumer products, including pesticide products, landscaping/yard products, and pet care products (NLM 2013). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).</td>
<td>NHANES and others have measured urinary 3-phenoxystyrenic acid (3 PBA), a metabolite of fenvalerate and other pyrethroid pesticides, in the urine of the general population and people who are occupationally exposed, and methods have been developed to measure fenvalerate and esfenvalerate in urine. In 99-00 and 01-02, NHANES measured urinary 3 PBA via organic liquid extraction and LC-MS/MS in 75% of samples, with LOD 0.1 µg/L (CDC 2009; Riederer et al. 2008). NHANES, 2003-2004 also measured 3 PBA, but withdrew the data “due to unacceptable measurement variance at or near the LOD” (CDC 2011). Other studies of 3-PBA levels are reviewed in the 3rd NHANES exposure report (CDC 2005) and by Egeghy (2011). Ramesh and Ravi (2004) tested 73 blood samples from occupationally exposed people via negative ion channel ionization GC-MS for fenvalerate and other pyrethroid pesticides, and did not detect any above the LOD of 0.2 µg/mL. Loper and Anderson (2003) described liquid chromatography with diode array detection for the detection of fenvalerate and other pyrethroid and pyrethrin pesticides in 5 mL of urine, with LODs between 0.002 and 0.04 µg/mL. Shan et al. (1999) described ELISA with SPE to measure PBA and esfenvalerate in urine, with LLOQ 1 µg/L.</td>
</tr>
<tr>
<td>4680-78-8</td>
<td>Guinea Green B</td>
<td>Miscellaneous</td>
<td>Guinea Green B is used to dye wool, silk, leather, paper, and wood. In the past, it was used as a food, drug and cosmetic dye to color gelatin desserts, frozen desserts, sweets and confections which did not contain fats and oils, bakery products and cereals, and drug capsules. However, its use as color additive for foods, drugs and cosmetics was forbidden in the USA in late 1966 and its use as a food additive was forbidden in Japan in 1967. It is considered to be unsafe for use in food throughout the world. In Western Europe, Guinea Green B can provisionally be used in cosmetics that do not come into contact with mucous membranes; and in Japan, it is used in externally applied cosmetics (NLM 2011).</td>
<td>No studies were found measuring biomarkers of exposure to Guinea Green B.</td>
</tr>
<tr>
<td>502-01-2</td>
<td>Hydrazine</td>
<td>Miscellaneous</td>
<td>The potential for exposure of the general population to hydrazine is low, but it may occur through inhalation of cigarette smoke or ingestion of trace amounts in processed foods (NTP 2011). Another possible exposure includes dermal contact with vapors and other products manufactured with hydrazine such as textile dyes, pharmaceuticals, and photography chemicals (NLM 2011). A major source of hydrazine to the environment is from discharge of cooling water from nuclear power facilities and, to a lesser degree, from fossil fuel-based power facilities (Environment Canada 2011), and it has been detected at low levels in wastewater (IARC 1999). It is listed as a Proposition 65 carcinogen (California OEHHA 2014). REACH SVHC Candidate List, with use in fuel, propellant, gas, corrosion inhibitors, and in polymerisation reactions (ECHA 2013).</td>
<td>No occupational or general-population studies could be found for hydrazine, though there was one study of blood hydrazine levels in humans after administration of specific drugs, as well as multiple methods-development studies on blood and urine. Blair et al. (1985), using GC-MS, detected hydrazine and 8-hydroxydeoxyguanosine in 8/8 volunteers taking isoniazid and 8/14 patients taking hydralazine chronically. Kirchhoff et al. (1993) used HPLC to test for hydrazine in plasma and serum and obtained LOD 1 ng/mL, and LLOQ 5ng/mL. Von Sassen et al. (1985) used HPLC to detect the metabolites acetylhydrazine and diacetylhydrazine in plasma, with DLs of 0.5 nmol/ml and 1 nmol/ml respectively. Von Sassen et al. (1985) also used HPLC to analyze urine, with DLs of 10 nmol/ml for acetylhydrazine and 20 nmol/ml for diacetylhydrazine. Seifart et al. (1995) used GCMS to detect hydrazine in unspecified (in abstract) “biological fluids,” with LLOQ 10ng/ml.</td>
</tr>
<tr>
<td>77-79-5</td>
<td>Isoprene</td>
<td>Miscellaneous</td>
<td>Isoprene is formed endogenously in humans, emitted from plants and trees, and is widely present in the environment at low concentrations. Sources of anthropogenic releases of isoprene to the atmosphere include ethylene production by petroleum processing, wood burning, oil fires, wood-burning stoves and fireplaces, other biomass combustion, tobacco smoke, gasoline, and exhaust of turbines and automobiles (NTP 2011). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).</td>
<td>Isoprene is believed to be involved in the cholesterol synthesis pathway (Stone et al. 1993) and is associated with factors including heart rate, sleep or wakefulness, recent exercise, and age (Cailleux et al. 1993; Kushch et al. 2008; Turner et al. 2006). It is therefore unlikely to be a good marker of exposure to products of combustion, though methods exist to study levels in blood and exhaled breath. Concentrations in blood samples from a general population range from 15 to 70 nmol/l with mean of 37 nmol/l and SD of 25 nmol/l (Cailleux et al. 1993). Csányi et al. (2001) predict that the blood concentration in nonexposed humans should be about 9.5 nmol/l. In the general population, concentration in exhaled breath was found to range from 0-474 ppb with a mean of 118 ppb and a SD of 68 ppb (Turner et al. 2006). For blood, the most sensitive method found was SMPS/GC-MS, with LOD between 0.02 and 0.1 nmol/l (Meriksch et al. 2001). The most sensitive method for breath was proton-ion-transfer-MS (PIT-MS) with an LOD between 0.002 and 0.04 µg/L.</td>
</tr>
<tr>
<td>CAS</td>
<td>Name</td>
<td>Chemical group</td>
<td>Exposure summary</td>
<td>Biomarker summary</td>
</tr>
<tr>
<td>------</td>
<td>-----------------</td>
<td>----------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>129-7-7</td>
<td>Leucomalachite green</td>
<td>Miscellaneous</td>
<td>The general public may become exposed to leucomalachite green through the consumption of fish treated with this compound, which is also used as an anti-bacterial agent in aquaculture (NTP 2004)). This compound is also used in processing malachite green, used for dyeing silk, wool, jute, cotton, and leather (NLM 2011). Also see malachite green.</td>
<td>No studies were found measuring malachite green or leucomalachite green biomarkers in humans. Several LC-based methods have been used on tissues of fish, shrimp, and other aquatic organisms (Andersen et al. 2005; Long et al. 2008; Mitrowska et al. 2005; Turnipseed et al. 2005; Wu et al. 2007; Zhu et al. 2007.), the most sensitive having a detection limit of 0.25 ng/g (Andersen et al. 2005).</td>
</tr>
<tr>
<td>2437-29-8</td>
<td>Malachite green</td>
<td>Miscellaneous</td>
<td>The general public may become exposed to malachite green through the consumption of fish treated with this compound, which is also used as an anti-bacterial agent in aquaculture (NTP 2004). Also used for dyeing silk, wool, jute, cotton, and leather (NLM 2011). See entry for leucomalachite green.</td>
<td>No studies were found measuring malachite green or leucomalachite green biomarkers in humans. Several LC-based methods have been used on tissues of fish, shrimp, and other aquatic organisms (Andersen et al. 2005; Long et al. 2008; Mitrowska et al. 2005; Turnipseed et al. 2005; Wu et al. 2007; Zhu et al. 2007), the most sensitive having a detection limit of 0.25 ng/g (Andersen et al. 2005).</td>
</tr>
<tr>
<td>93-15-2</td>
<td>Methyleugenol</td>
<td>Miscellaneous</td>
<td>Methyleugenol is a naturally occurring substance, present in many essential oils, including rose, pimento, basil, hyacinth, citronella, anise, nutmeg, mace, cinnamon leaves, pixuri seeds, and laurel fruits and leaves. It is a registered food additive used in commercial products as a flavorant and a fragrance at small concentrations in jellies, baked goods, nonalcoholic beverages, chewing gum, candy, pudding, relish, and ice cream (NTP 2011; US FDA 2013). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).</td>
<td>Two general-population studies were found measuring methyleugenol (ME) levels in blood. One study described detection in rat liver. Barr et al. (2000) described SPE-GC-MS, with a DL of 3.1 pg/g wet weight. Testing a subset of the US NHANES population, Barr et al. (2000) found ME in 98% of serum samples, with a mean concentration of 24 pg/g, and a maximum of 390 pg/g. Schecter et al. (2004) found that ME levels in blood increased from a mean of 16.2 pg/g fasting to a mean of 63.9 pg/g 15 minutes after a high-ME snack. Gardner (1996) described ELISA and immunoblotting to detect ME in rat liver.</td>
</tr>
<tr>
<td>96-95-3</td>
<td>Nitrobenzene</td>
<td>Miscellaneous</td>
<td>Nitrobenzene has been detected in surface and groundwater (IARC 1996a). The general public may be exposed to nitrobenzene in the environment through inhalation of ambient air, ingestion of water, or dermal contact with products or water containing nitrobenzene. Nitrobenzene is found in soaps and shoe and metal polishes and is used as a preservative in spray paints, constituent of floor polishes, substitute for almond essence, and in the perfume industry (NLM 2011; NTP 2011). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).</td>
<td>NHANES has measured nitrobenzene in blood samples from the general population, and other studies have measured nitrobenzene exposure in blood of occupationally or otherwise exposed humans. Methods also exist for determination of nitrobenzene in urine and bone marrow. NHANES has used HS-SPME-GC-MS on 3 mL (minimum) to 10 mL (optimal) whole blood, but less than 5% of the population had levels above the LOD (0.3 ng/mL) (Blount et al. 2006; CDC 2008b, 2009). Thier et al. (2001) measured aniline, benzidine, and 4-aminoazopyridine adducts of hemoglobin and human serum albumin in 80 male employees of a nitrobenzene reduction plant, finding a large difference between smokers and non-smokers in hemoglobin-ADP adducts but not in aniline adducts, which they concluded were dominated by occupational exposure. Martinez et al. (2003) used GC-FID and GC-MS on the blood of a patient suffering from symptoms of poisoning, and detected 3.2 µg nitrobenzene/mL whole blood 48 hours after the eventually fatal dose. Dengwall and Kadam (1980) used microdiffusion to measure nitrobenzene in urine, with LOD 0.2 µg/L. Chen et al. (2004) detected nitrobenzene and other nitro metabolites of benzene in the bone marrow of mice that had been treated with benzene 1 hour before.</td>
</tr>
<tr>
<td>75-52-5</td>
<td>Nitromethane</td>
<td>Miscellaneous</td>
<td>The general public may be exposed by inhalation of nitromethane in motor vehicle exhaust and cigarette smoke (NTP 2011). Exposures may also occur from the use of solvents, aerosol propellants, and fuels containing nitromethane (IARC 2000b). It is found in craft model fuels (NLM 2013) and is listed as an ingredient in manicuring preparations and rubber adhesives. Nitromethane has been detected in air, surface water, and drinking water. It is listed as a Proposition 65 carcinogen (California OEHHA 2014).</td>
<td>One study has measured nitromethane in blood from the general population. Alwis et al. (2008) used SPME-GC-HRMS with LOD 0.01 µg/L to measure nitromethane in the blood of 632 people with no known occupational exposure. Concentrations ranged from 0.28-3.97 µg/L, with a median of 0.66 µg/L. The authors of the study point out that nitromethane in the blood can indicate exposure to nitromethane itself or to halonitromethanes, and that it can be formed from peroxynitrite. Other studies (e.g. Mullins and Hammett-Stabler 1998) have noted that high blood levels of nitromethane can interfere with creatinine measurements.</td>
</tr>
<tr>
<td>CAS</td>
<td>Name</td>
<td>Chemical group</td>
<td>Exposure summary</td>
<td>Biomarker summary</td>
</tr>
<tr>
<td>---------</td>
<td>---------------------------</td>
<td>----------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>924-16-3</td>
<td>n-Nitroso-di-n-butylamine</td>
<td>Miscellaneous</td>
<td>Estimates indicate that air, diet, and smoking contribute to potential human exposure to n-nitroso-di-n-butylamine at levels of a few µg per day. This compound and other n-nitrosamines are frequently produced during rubber processing and may be present as contaminants in the final rubber product. Nitrosamines present in pacifiers and baby bottle nipples can migrate from the pacifier or nipple into saliva, which could result in ingestion of nitrosamines (IARC 1993c; NTP 2005). Nitrosamines are found in cosmetics, lotions, shampoos, cutting fluids, certain pesticides, antifreeze, cooked fish, pork luncheon meat, the interior of new cars, cigarette smoke, and an aqueous rubber extract; nitrosamines are formed within these products by reactions of precursors or introduced through the use of contaminated raw materials (NLM 2011; NTP 2011). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).</td>
<td>No studies were found using biomarkers for n-nitroso-di-n-butylamine</td>
</tr>
<tr>
<td>88-72-2</td>
<td>o-Nitrotoluene</td>
<td>Miscellaneous</td>
<td>The general population may be exposed to o-nitrotoluene as a result of its occurrence in the environment from inadvertent spills of o-nitrotoluene or chemical mixtures containing o-nitrotoluene, emissions directly into the environment, or breakdown products of dinitrotoluenes (DNT) and trinitrotoluenes (TNT) (NTP 2011). Exposure to nitrotoluenes can also occur during their production and use, although few data are available. Consumer products that may contain this chemical include: art materials, putty, glazing, wood preservatives and brush cleaners (US EPA 2010b). It has been detected in effluents from the manufacture or use of nitrotoluenes and in surface and groundwater (IARC 1996b) and has been detected in U.S. air and water (NTP 2011). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).</td>
<td>Two studies were found measuring exposure to o-nitrotoluene (2NT) in the blood or urine of exposed workers. Jones et al. (2005) measured hemoglobin adducts in the blood of Chinese workers exposed to nitrotoluenes, finding that the Hb-2NT adduct was the most abundant mononitrotoluene adduct. Jones et al. (2005) found nitrobenzoic acid metabolites of 2NT in the urine of 96% of exposed workers.</td>
</tr>
<tr>
<td>1120-71-4</td>
<td>Propane sultone</td>
<td>Miscellaneous</td>
<td>Consumers are potentially exposed to residues of propane sultone when using detergents, corrosion inhibitors, and other products manufactured from 1,3-propane sultone (NTP 2011). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).</td>
<td>No studies were found measuring biomarkers of exposure to propane sultone</td>
</tr>
<tr>
<td>95-06-7</td>
<td>Sulfallate</td>
<td>Miscellaneous</td>
<td>Sulfallate was used as an herbicide until the early 1990s and is no longer used in the United States. In the past, the general population may have been exposed to sulfallate through ingestion of residues in food crops (NTP 2011). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).</td>
<td>No studies were found using biomarkers of exposure to sulfallate.</td>
</tr>
<tr>
<td>51-79-6</td>
<td>Urethane</td>
<td>Miscellaneous</td>
<td>The general population may be exposed to urethane via ingestion of fermented foods and alcoholic beverages. Urethane is used as a solvent for organic materials and co-solvent in the manufacture of pesticides, fumigants, and cosmetics. It has been found in foods made by a fermentation process, including ale, beer, bread, wine, soy sauce, yogurt, and olives (NLM 2011; NTP 2011). It is listed as a Proposition 65 carcinogen (California OEHHA 2014).</td>
<td>No studies were found using specific biomarkers to measure exposure to urethane. Sun et al. (2006) and Bartsch et al. (2000) describe measurement of etheno-DNA adducts in urine as markers of exposure to urethane, vinyl chloride, or endogenous oxidative stress processes. Bartsch et al. (2000) reviews measurement of etheno-DNA adducts in other organs.</td>
</tr>
<tr>
<td>CAS</td>
<td>Name</td>
<td>Chemical group</td>
<td>Exposure summary</td>
<td>Biomarker summary</td>
</tr>
<tr>
<td>-----</td>
<td>------</td>
<td>----------------</td>
<td>------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>NA</td>
<td>X-rays, gamma rays (ionizing radiation)</td>
<td>Miscellaneous</td>
<td>The greatest exposure of the general population to X-rays and gamma rays comes from natural terrestrial radiation. The next most significant source is the use of X-rays and radiopharmaceuticals in various medical diagnostic and therapeutic procedures. Exposures may also occur from the generation of energy by nuclear reactors or accidents at these facilities. Exposures from the atmospheric testing of nuclear weapons have diminished (NTP 2011).</td>
<td>No methods are currently available that detect internal ionizing radiation exposure retrospectively, although research is underway to develop a method that can detect recent exposure by evaluating expression of DNA-repair genes (Budworth et al. 2012).</td>
</tr>
</tbody>
</table>

BMI = body mass index; CDC = Centers for Disease Control and Prevention; EI = electron impact; ELISA = enzyme linked immunosorbent assay; EPA = Environmental Protection Agency; ESI = electrospray ionization; ETS = environmental tobacco smoke; FD = fluorescence detection; FI-CL = flow injection chemiluminescence; FID = flame ionization detection; GC = gas chromatography; HF = hollow fiber; HPLC = high-performance liquid chromatography; HR MS = high-resolution mass spectrometry; HS = headspace; IAC = immunoaffinity chromatography; IARC = International Agency for Research on Cancer; IOM = Institute of Medicine; LC = liquid chromatography; LLE = liquid-liquid extraction; LLOQ = lower limit of quantification; LOD = limit of detection; MS = mass spectrometry; MS/MS = tandem MS; NCI = negative-ion chemical ionization; NHANES = National Health and Nutrition Examination Survey; NIOSH = National Institute for Occupational Safety and Health; NTP = National Toxicology Program; PAH = polycyclic aromatic hydrocarbon; PFC = perfluorinated chemical; PIT MS = proton ion transfer MS; RIA = radio immunoassay; Rp = reverse phase; SIM = selected ion monitoring; SPE = solid phase extraction; SPME = solid phase micro extraction; TLC = thin layer chromatography; UPLC = ultra high-performance liquid chromatography; UV = ultraviolet detection; VOC = volatile organic compound.
### Table S2. Guide to breast cancer cohort studies (studies assessing breast cancer incidence, recurrence, or survival).

<table>
<thead>
<tr>
<th>Study name</th>
<th>Institution (PI)</th>
<th>Funder(s)</th>
<th>Study population</th>
<th>Study period</th>
<th>Measurements</th>
<th>Health outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Avon Longitudinal Study of Parents and Children (ALSPAC; Children of the 90s)</td>
<td>University of Bristol (George Davey Smith)</td>
<td>UK Medical Research Council, Wellcome Trust, University of Bristol</td>
<td>13,761 pregnant women near Avon, England recruited in 1991-92, along with their children and partners.</td>
<td>Ongoing research: 1991-present</td>
<td>Measurements include blood, urine, hair, nail, saliva, placenta samples; lymphoblastoid cell lines; DNA; questionnaire and clinical data.</td>
<td>Outcomes include development and puberty outcomes in children and breast and other cancer in mothers.</td>
</tr>
<tr>
<td>Agricultural Health Study</td>
<td>NCI (Michael Alvanaja and Laura Beane Freeman), NIEHS (Dale Sandler and Jane Hoppin), US EPA (Kent Thomas), NIOSH (Cynthia Hines)</td>
<td>NCI, NIEHS, NIOSH, US EPA</td>
<td>89,000 private pesticide applicators (farmers) and their spouses in Iowa and North Carolina, as well as commercial pesticide applicators in Iowa.</td>
<td>Ongoing research: 1993-present</td>
<td>Measurements include surveys of smoking, drinking and diet; buccal rinse samples; information on occupational practices; lifestyle factors; pesticide exposure; family history of cancer; reproductive history; agricultural exposure; and general health.</td>
<td>Outcomes include cancer (breast, leukemia, myeloma, non-Hodgkin's lymphoma, melanoma of the skin, lung, colon, rectal, pancreas, bladder, and prostate), asthma, neurologic disease, injury, mortality, and adverse reproductive effects.</td>
</tr>
<tr>
<td>Arteriosclerosis Risk in Communities (ARIC)</td>
<td>Johns Hopkins (Elizabeth A. Platz), University of North Carolina (David Couper)</td>
<td>NIH</td>
<td>15,792 participants (55% female, 27% African-American) aged 45-64 in 1987 recruited from North Carolina, Mississippi, Minneapolis, and Maryland; 3,145 participants diagnosed with cancer by 2006.</td>
<td>Ongoing research: 1987-present</td>
<td>Measurements include blood and urine samples, clinical exams, food frequency questionnaires; tissue blocks to be collected from cancer cases.</td>
<td>This cohort was originally established to study arteriosclerosis, but has data on cancer incidence and recently received funding to collect and analyze more detailed information about cancer diagnoses and treatments.</td>
</tr>
<tr>
<td>Black Women's Health Study</td>
<td>Slone Epidemiology Center at Boston University (Lynn Rosenberg and Julie Palmer), Lombardi Cancer Center at Georgetown University (Lucile Adams-Campbell)</td>
<td>NIH</td>
<td>59,000 black women in US. 15,792 participants (55% female, 27% African-American) aged 45-64 in 1987 recruited from North Carolina, Mississippi, Minneapolis, and Maryland; 3,145 participants diagnosed with cancer by 2006.</td>
<td>Ongoing research: 1995-present</td>
<td>Measurements include questionnaires every two years, medical records (if disease of interest), cancer registry data. Validation studies: dietary study (400), physical activity study (100+), and buccal cell samples (26,800).</td>
<td>Outcomes include breast and other cancers, and nonmalignant conditions that disproportionately affect black women.</td>
</tr>
<tr>
<td>Breakthrough Generations Study</td>
<td>University of London Institute of Cancer Research (Anthony Swerdlow and Alan Ashworth)</td>
<td>University of London Institute of Cancer Research, Breakthrough Breast Cancer</td>
<td>112,049 British women, ages 16-102 at recruitment; 30% are first-degree relatives of another study member.</td>
<td>Ongoing research: recruitment 2003-2011, follow-up expected to continue at least through 2050</td>
<td>Measurements include questionnaires about current exposures, historical exposures, and anthropomorphic measurements every 2 1/2 years, blood samples at enrollment (follow-up blood samples planned).</td>
<td>Outcomes include breast and other cancer incidence and mortality, as well as details including histology, grade information, and hormone receptor information. Information on other illnesses and cause of death also collected.</td>
</tr>
<tr>
<td>Breast Cancer Family Registry</td>
<td>National Cancer Institute (Sheri Dixon Schully), Columbia University (Mary Beth Terry), Northern California Cancer Center (Esther John), Fox Chase Cancer Center (Mary Daly), University of Utah (Saundra Buys), University of Melbourne (John Hopper), Cancer Care Ontario (Irene Andrulis)</td>
<td>NCI</td>
<td>40,000 participants from more than 13,000 families, enrolled from population-based case families, population-based control families, and clinic-based families.</td>
<td>Ongoing research: 1996-present</td>
<td>Measurements include family history information, epidemiological and clinical data, and biological specimens (blood and/or buccal samples and tumor tissue).</td>
<td>Outcomes include breast cancer.</td>
</tr>
<tr>
<td>Study name</td>
<td>Institution (PI)</td>
<td>Funder(s)</td>
<td>Study population</td>
<td>Study period</td>
<td>Measurements</td>
<td>Health outcomes</td>
</tr>
<tr>
<td>-------------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>----------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>California Flight Attendants Study</td>
<td>Northern California Cancer Center (Peggy Reynolds)</td>
<td>California Breast Cancer Research Program</td>
<td>Residents of CA and members of the Association of Flight Attendants (AFA).</td>
<td>1988-1995</td>
<td>Measurements include work history information and matching of AFA members with the California Cancer Registry.</td>
<td>Outcomes include breast and other cancers.</td>
</tr>
<tr>
<td>California Teachers Study</td>
<td>City of Hope Comprehensive Cancer Center (Leslie Bernstein), California Department of Health Services, Northern California Cancer Center, UC Irvine, and USC</td>
<td>NIH, NCI, others</td>
<td>133,479 current and former public school teachers or administrators who participate in the California State Teachers Retirement System (STRS); ages range from 22 to 104 (mode 50-60). &gt;12,000 cancer diagnoses (4,576 invasive breast cancer diagnoses, 1,091 in situ breast cancer diagnoses).</td>
<td>Ongoing research: 1995-present (funded through 2016)</td>
<td>Measurements include questionnaires, cancer registry data, mortality data, blood samples for 1,800 breast cancer cases and 2,600 controls, 3,000 buccal cell samples, 400 toenail samples, and a measurement substudy of 328 (304 with urine samples).</td>
<td>Outcomes include breast and other cancers, and general health.</td>
</tr>
<tr>
<td>Canadian National Breast Screening Study (CNBSS)</td>
<td>University of Toronto (Anthony Miller), Albert Einstein College of Medicine (Tom Rohan)</td>
<td>Canadian Breast Cancer Foundation</td>
<td>89,835 women living in 12 Canadian cities who were between 40-59 years at enrollment (1982-1987). 50,430 women age 40-49 and 39,405 age 50-59. 56,837 completed a self administered dietary questionnaire.</td>
<td>1980-1987 (recruitment); continued passive follow-up using national databases</td>
<td>Measurements include breast physical exam, mammography, pathology results, questionnaire data, food frequency questionnaire, demographic information, breast and other cancer incidence and cohort mortality.</td>
<td>Outcomes include breast, lung, and other cancers.</td>
</tr>
<tr>
<td>Canadian Partnership for Tomorrow</td>
<td>Various</td>
<td>Canadian Partnership Against Cancer, regional institutions</td>
<td>Over 250,000 Canadians in five regions of Canada.</td>
<td>Ongoing research: 2001-present</td>
<td>Measurements include blood, saliva, varied questionnaire and clinical data depending on sub study.</td>
<td>Outcomes include breast and other cancers.</td>
</tr>
<tr>
<td>Cancer Prevention Study 3 (CPS 3)</td>
<td>American Cancer Society (Alpa Patel)</td>
<td>American Cancer Society</td>
<td>Expected size of 500,000 men and women age 30-65 with no personal history of cancer; goal of at least 25% minority participation.</td>
<td>New research: enrollment ongoing, 20+ years follow-up planned</td>
<td>Measurements include baseline survey, waist measurement and blood sample. Questionnaire data will be collected every 2-3 years. Participants reporting cancer will be verified through medical records or cancer registry linkage.</td>
<td>Outcomes include all causes of mortality and cancer incidence.</td>
</tr>
<tr>
<td>Cancer Prevention Study II (CPS II)</td>
<td>American Cancer Society (Susan Gapstur)</td>
<td>American Cancer Society</td>
<td>1.2 million American men and women enrolled in 1982.</td>
<td>Ongoing research: 1982-present</td>
<td>Measurements include the 1982 baseline questionnaire; additional questionnaires in 1992, 1997, and every two years thereafter (CPS-II Nutrition Cohort); blood samples (39,380) and buccal cells (from an additional 67,000).</td>
<td>Outcomes include mortality from breast and other cancers (1982-present). Incidence of breast cancer and other cancers since 1992 for CPS-II Nutrition Cohort (~98,000 women, ~84,000 men).</td>
</tr>
<tr>
<td>Study name</td>
<td>Institution (PI)</td>
<td>Funder(s)</td>
<td>Study population</td>
<td>Study period</td>
<td>Measurements</td>
<td>Health outcomes</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>--------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>-------------------------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Child Health and Development Study (CHDS)</td>
<td>Public Health Institute (Barbara Cohn)</td>
<td>NIH</td>
<td>Women living near Oakland, CA who were under the care of Kaiser Permanente Health Plan were enrolled when they first found out they were pregnant. 15,528 families, 20,530 pregnancies, 20,754 babies and 19,044 live births enrolled from 1959 to 1967.</td>
<td>Ongoing research: 1959-present</td>
<td>Measurements include prenatal maternal interviews, clinical assessments, biological specimens, placental pathologies, medical histories (physical and mental), developmental, emotional and behavioral assessments, and reproductive outcomes.</td>
<td>Outcomes include pregnancy and infant health and development, early experiences and disease/condition onset, and cancer and mortality in fathers, mothers and now-adult children.</td>
</tr>
<tr>
<td>CLUE I &amp; II</td>
<td>Bloomberg School of Public Health, John Hopkins University (Kala Visvanathan)</td>
<td>Johns Hopkins</td>
<td>25,802 participants in 1974, 32,898 participants in 1989 (overlap of 8395); over half female. Both samples have &quot;reasonable representation of the general county population.&quot;</td>
<td>1974 to 2007 (some information from 1963 and 1965)</td>
<td>Measurements include blood sample, blood pressure and questionnaires.</td>
<td>Outcomes include breast and other cancers, CVD, and stroke.</td>
</tr>
<tr>
<td>Columbia, Missouri Serum Bank</td>
<td>NCI (Louise Brinton)</td>
<td>NCI</td>
<td>7,224 women living in and around Columbia, MO.</td>
<td>Enrollment in 1977-1987</td>
<td>Measurements include hormones measured in serum collected from 1977-1987 and follow-up questionnaires.</td>
<td>Outcomes of interest include breast cancer.</td>
</tr>
<tr>
<td>DES Combined Cohort Follow-up Study</td>
<td>Various researchers</td>
<td>NCI, CDC</td>
<td>Multiple cohort studies combined; NCI still follows approximately 15,000 members of the combined cohort study.</td>
<td>Ongoing research: 1971-present</td>
<td>Measurements include questionnaires about reproductive health.</td>
<td>Outcomes include breast and other cancers and reproductive effects.</td>
</tr>
<tr>
<td>European Prospective Investigation into Cancer and Nutrition (EPIC)</td>
<td>IARC, WHO (Elio Riboli)</td>
<td>European Commission &quot;Europe Against Cancer&quot; Programme</td>
<td>520,000 men and women in 10 European countries (Denmark, France, Germany, Greece, Italy, The Netherlands, Norway, Spain, Sweden and UK); participants mostly age 20 or older at enrollment (1993-1999).</td>
<td>Ongoing research: 1992-present</td>
<td>Measurements include a baseline survey; anthropometric assessment (e.g. height, weight, hip and waist measurements); and blood samples.</td>
<td>Outcomes include chronic diseases, including breast and other cancers.</td>
</tr>
<tr>
<td>Framingham Heart Study</td>
<td>NHLBI (Daniel Levy and Christopher O'Donnell) and Boston University (Philip Wolf, William Kannel, Emelia Benjamin, Joanne Murabito, and Ralph D'Agostino)</td>
<td>NHLBI</td>
<td>Original cohort: 5,209 men and women from Framingham, MA ages 30 to 62 in 1948. Offspring cohort: 5,124 adult children of original cohort and their spouses, enrolled in 1971. Generation III cohort: 4,095 adult grandchildren. Omni Cohort 1: 506 minority men and women enrolled in 1994 to increase ethnic diversity of participants. Omni Cohort 2: 402 participants added to the original omni cohort.</td>
<td>Ongoing research: 1948-present</td>
<td>Measurements include medical histories (including hormone use), physical exams, and laboratory tests (plasma) every 2 years.</td>
<td>Outcomes include CVD and other chronic outcomes, including breast cancer.</td>
</tr>
<tr>
<td>Study name</td>
<td>Institution (PI)</td>
<td>Funder(s)</td>
<td>Study population</td>
<td>Study period</td>
<td>Measurements</td>
<td>Health outcomes</td>
</tr>
<tr>
<td>------------</td>
<td>------------------</td>
<td>-----------</td>
<td>------------------</td>
<td>--------------</td>
<td>--------------</td>
<td>----------------</td>
</tr>
<tr>
<td>General COhort of Adults in NORway (CONOR)</td>
<td>Norwegian University of Science and Technology (Lars J. Vatten), The Norwegian Cancer Registry (Giske Ursin)</td>
<td>Norwegian Institute of Public Health, University of Tromse, Norwegian University of Science and Technology in Trondheim, University of Bergen, and University of Oslo</td>
<td>185,000 participants in different parts of Norway.</td>
<td>Ongoing research: 1993 to present</td>
<td>Measurements include blood samples, extracted DNA, cancer data and smoking, body mass and physical activity data.</td>
<td>CONOR is a collaboration studying rare diseases and cancer; member studies may include other outcomes.</td>
</tr>
<tr>
<td>Great Lakes Human Health Effects Research Program (GLHHERP)</td>
<td>ATSDR (Heraline Hicks), multiple funded organizations</td>
<td>ATSDR</td>
<td>People residing in the Great Lakes basin (multiple cohorts, multiple studies).</td>
<td>Ongoing research: 1992-present</td>
<td>Measurements include surveys, gene function and biomarkers measured in blood, and morbidity/mortality data (depends on specific research project).</td>
<td>Outcomes include health effects related to fish consumption (depends on specific research project).</td>
</tr>
<tr>
<td>Hormones and Diet in the Etiology of Breast Cancer Risk (ORDET)</td>
<td>Instituto Nazionale Per lo Studio e la Cura dei Tumori (Franco Berrino, Paola Muti, Vittorio Krogh)</td>
<td>NCI, US Army Medical Research and Material Command</td>
<td>10,786 Italian women without any history of cancer or hormone therapy, age 35-69 at enrollment; about 130 breast cancer cases with blood samples.</td>
<td>1987-2003 (enrollment 1987-1992)</td>
<td>Measurements include questionnaires, anthropometric variables, blood samples, and urine samples.</td>
<td>Outcomes include incident breast cancer.</td>
</tr>
<tr>
<td>Iowa Women’s Health Study</td>
<td>University of Minnesota (Kim Robien)</td>
<td>NCI</td>
<td>41,836 Iowa women, age 55-69 in 1986; &gt;2,900 incident breast cancers by 2007.</td>
<td>Ongoing research: 1985-present</td>
<td>Measurements include surveys (one at baseline and 5 follow-ups), DNA (limited number of participants), and water samples.</td>
<td>Outcomes include CVD, chronic disease, and cancer, including breast cancer.</td>
</tr>
<tr>
<td>Janus Serum Bank</td>
<td>Cancer Registry of Norway, Institute of Population-based Cancer Research (Hilde Langseth)</td>
<td>Cancer Registry of Norway</td>
<td>317,000 Norwegians comprising blood donors in Oslo area and participants in past studies; 52,500 donors diagnosed with cancer by 2009.</td>
<td>Ongoing research: Specimens collected 1972-2004, with ongoing collection from earlier donors who have developed cancer since donating.</td>
<td>Measurements include blood samples.</td>
<td>Outcomes include cancers, recorded in Norwegian Cancer Registry.</td>
</tr>
<tr>
<td>Japan Public Health Center-Based Prospective Study (JPHC)</td>
<td>Research Center for Cancer Prevention and Screening, National Cancer Center (Shoichiro Tsugane)</td>
<td>Grant-in-Aid for Cancer Research from the Ministry of Health, Labor and Welfare, Japan</td>
<td>140,420 residents of 29 municipalities within 11 public health center (PHC) areas nationwide.</td>
<td>Ongoing research: 1990-present</td>
<td>Measurements include three surveys of lifestyle habits to date, at five-year intervals, blood samples and health check-up data from 60,000 people.</td>
<td>Outcomes include mortality, incidence of cancer, cerebrovascular disease and ischemic heart disease, diabetes mellitus, periodontal disease, age-related cataract, vertebral fracture, and other chronic diseases.</td>
</tr>
<tr>
<td>Kaiser Research Program on Genes, the Environment and Health (RPGEH)</td>
<td>Kaiser Permanente (Cathy Schaefer)</td>
<td>Community Benefit Program of Kaiser Permanente, Robert Wood Johnson Foundation, Wayne and Gladys Valley Foundation, Ellison Medical Foundation</td>
<td>500,000 Northern California Kaiser Permanente members (men and women). Current enrollment is 200,000.</td>
<td>Ongoing research: 2007-present</td>
<td>Measurements include medical, lifestyle, demographic, environmental and, in some cases, genetic information from saliva and blood samples.</td>
<td>Outcomes include CVD, cancer, diabetes, high blood pressure, Alzheimer’s disease, asthma and many others.</td>
</tr>
<tr>
<td>Study name</td>
<td>Institution (PI)</td>
<td>Funder(s)</td>
<td>Study population</td>
<td>Study period</td>
<td>Measurements</td>
<td>Health outcomes</td>
</tr>
<tr>
<td>---------------------------------------------------------------------------</td>
<td>----------------------------------------------</td>
<td>--------------------------------</td>
<td>-----------------------------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>--------------------------------------------------------------------------------------------------</td>
<td>------------------------------------------------------</td>
</tr>
<tr>
<td>Kathleen Cunningham Foundation Consortium for Research into Familial</td>
<td>Various</td>
<td>Australian National Health and</td>
<td>Members of 1,600 families with multiple breast cancer cases.</td>
<td>Ongoing</td>
<td>Measurements include genetic, epidemiological, medical, psychosocial and clinical follow-up data,</td>
<td>Outcomes include familial breast, ovarian, prostate</td>
</tr>
<tr>
<td>Aspects of Breast Cancer (kConFab) biospecimen and data resource</td>
<td></td>
<td>Medical Research Council,</td>
<td></td>
<td>research:</td>
<td>biospecimens.</td>
<td>and pancreatic cancer.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>State Cancer Councils, National</td>
<td></td>
<td>1997-present</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Breast Cancer Foundation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Love/Avon Army of Women</td>
<td>Dr. Susan Love Research Foundation</td>
<td>Avon Foundation</td>
<td>1 million women (~373,000 as of July 2013).</td>
<td>Ongoing</td>
<td>Measurements vary depending on research project.</td>
<td>Outcomes vary depending on research project.</td>
</tr>
<tr>
<td>Massachusetts Women's Health Study</td>
<td>New England Research Institutes (Sonja</td>
<td>NIH/NIA</td>
<td>8,000+ MA women born between 1926 and 1936 (age 45-54); follow up of all 2,572 premenopausal women.</td>
<td>1962-1967 and</td>
<td>Measurements include cross-sectional survey (8,000+), telephone interviews every 9 months for 54</td>
<td>Outcomes include timing of menopause and potentially</td>
</tr>
<tr>
<td></td>
<td>McKinlay)</td>
<td></td>
<td></td>
<td>1966-1996 for a sub-cohort with physiological measures</td>
<td>months (2,572) and then annually (~450).</td>
<td>menopause-related experiences.</td>
</tr>
<tr>
<td>Mayo Mammography Health Study</td>
<td>Mayo Clinic College of Medicine (Celine M.</td>
<td>Mayo Clinic Cancer Center</td>
<td>19,924 women ages 35 and over, living in Minnesota, Iowa, and Wisconsin, without a history of breast</td>
<td>Ongoing</td>
<td>Measurements include mammograms, self-administered questionnaire, and blood samples from over</td>
<td>Outcomes include breast and other cancers.</td>
</tr>
<tr>
<td>Melbourne Collaborative Cohort Study (MCCS, a.k.a. Health 2020)</td>
<td>Cancer Council Victoria (Graham Giles)</td>
<td>Cancer Council Victoria</td>
<td>41,500 people (24,500 women and 17,000 men) age 40-69; southern European migrants (25% of participants)</td>
<td>Ongoing</td>
<td>Measurements include baseline interview, physical measurements, food frequency questionnaire and</td>
<td>Outcomes include cancer and all-cause mortality.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>were deliberately over-sampled to increase the range of lifestyle exposures and genetic variation.</td>
<td>research:</td>
<td>blood sample; follow-up questionnaire and blood sample; follow-up questionnaire administered 3-4 years after baseline; second physical follow-up administered 12-14 years after baseline.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1990-present</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MESA (Multi-Ethnic Study of Atherosclerosis; including MESA Family,</td>
<td>University of Washington - Coordinating</td>
<td>NHLBI</td>
<td>6,814 multi-ethnic (White, Black, Hispanic, Chinese) men and women ages 45-84 from six field centers</td>
<td>2000-2009</td>
<td>Measurements include clinical examinations, blood samples, urine samples, dietary surveys, ECGs, and DNA.</td>
<td>Outcomes include CVD.</td>
</tr>
<tr>
<td></td>
<td>Center (Richard Kronmal), Columbia Johns</td>
<td></td>
<td>across the US.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hopkins, Wake Forest, Northwestern, UCLA,</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>University of Minnesota</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Michigan Long-Term PBB Study</td>
<td>Michigan Department of Community Health,</td>
<td>CDC, NIH, and US EPA</td>
<td>4,000 Michigan residents accidentally exposed to PBB in 1973, including 1,900 women and their</td>
<td>1977 (cohort</td>
<td>Measurements include blood samples, health outcomes, and interviews.</td>
<td>Outcomes include effects of PBB on exposed women's</td>
</tr>
<tr>
<td></td>
<td>Emory University (Michele Marcus)</td>
<td></td>
<td>daughters.</td>
<td>identified)-2011; 1996-1999 additional study on EDCs conducted</td>
<td></td>
<td>reproductive health and chronic diseases including breast cancer.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multietnic/Minority Cohort Study of Diet and Cancer</td>
<td>University of Hawaii-Manoa (Laurence Kolonel)</td>
<td>NCI</td>
<td>215,000 men and women primarily of African-American, Japanese, Latino, Native Hawaiian, and Caucasian origin.</td>
<td>1993-2008</td>
<td>Measurements include a baseline survey, a subset of dietary surveys, and blood and urine samples for a subset (70,000).</td>
<td>Outcomes include breast and other cancers.</td>
</tr>
<tr>
<td>New York University Women's Health Study (NYUWHS)</td>
<td>New York University School of Medicine (Anne</td>
<td>NCI</td>
<td>14,274 women age 35-65 at enrollment (1985-1991).</td>
<td>Ongoing</td>
<td>Measurements include baseline and follow-up questionnaires with a focus on environmental factors and a blood sample at recruitment.</td>
<td>Outcomes include breast cancer and other chronic</td>
</tr>
<tr>
<td></td>
<td>Zeleniuch-Jacquotte)</td>
<td></td>
<td></td>
<td>research:</td>
<td></td>
<td>diseases.</td>
</tr>
<tr>
<td>Study name</td>
<td>Institution (PI)</td>
<td>Funder(s)</td>
<td>Study population</td>
<td>Study period</td>
<td>Measurements</td>
<td>Health outcomes</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>-------------------------------------------------------</td>
<td>-------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>----------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Nurses' Health Study I (NHS I)</td>
<td>Channing/HMS/ Brigham and Women's Hospital (Susan Hankinson)</td>
<td>NCI, NIH</td>
<td>122,000 female, married registered nurses, age 30-55 in 1976, who resided in the 11 most populous states.</td>
<td>Ongoing research: 1976-present</td>
<td>Measurements include surveys every two years focusing on menopausal status, smoking and hormone use; dietary surveys (1980, 1984, 1986 and every four years since); Quality of Life surveys (1992 and every four years since); toenail samples (68,000 sets in 1982-1984); and blood (33,000 samples in 1989-1990 and 18,700 samples in 2000-2001).</td>
<td>Outcomes include breast and other cancers, CVD, and other chronic diseases and conditions.</td>
</tr>
<tr>
<td>Nurses' Health Study II (NHS II)</td>
<td>HSPH (Walter Willett)</td>
<td>Originally NIH</td>
<td>116,686 female registered nurses age 25-42 in 1989.</td>
<td>Ongoing research: 1989-present</td>
<td>Measurements include surveys every two years focusing on oral contraceptive use, diet, smoking, pregnancies, and menopausal status; food frequency surveys start in 1991 and continue every four years since; Quality of Life surveys in 1993 and 1997; and blood and urine samples (30,000) in late 1990s.</td>
<td>Outcomes include breast cancer and other diseases.</td>
</tr>
<tr>
<td>Nurses' Health Study III (NHS III)</td>
<td>Channing/HMS/HSPH (Walter Willett)</td>
<td>Internal funding</td>
<td>Female nurses (including RNs, NPs, and LPN/LVNas) and nursing students in the US and Canada (age 20-46). Goal of 100,000 participants.</td>
<td>New research (currently in recruitment/pilot study phase)</td>
<td>Measurements include web-based surveys every six months, and diet and lifestyle information for sub-study of women who become pregnant.</td>
<td>Outcomes include breast cancer and general chronic diseases.</td>
</tr>
<tr>
<td>Seventh-day Adventist Cohort Study: Cancer Epidemiology in Adventists - A Low Risk Group</td>
<td>Loma Linda University School of Health Research (Gary Fraser)</td>
<td>Loma Linda University, World Cancer Research Fund</td>
<td>71,000 white and 25,000 black adult Seventh-day Adventists in the US.</td>
<td>Ongoing research: 2002-present</td>
<td>Measurements include questionnaires with special attention paid to diet. Some blood, urine and subcutaneous fat samples.</td>
<td>Outcomes include cancers of the breast, prostate, and colon.</td>
</tr>
<tr>
<td>Seveso Women's Health Study</td>
<td>UC Berkeley (Brenda Eskenazi)</td>
<td>NIEHS</td>
<td>Women age 0-40 in 1976 who lived in Zones A or B during the Seveso Plant Explosion.</td>
<td>Ongoing research: 1996-present</td>
<td>Measurements include TCDD levels in serum, interviews focusing on reproductive history, gynecological examinations, bone density exams (subset), and clinical chemistries, including thyroid.</td>
<td>Outcomes include endometriosis, menstruation, menarche, menopause, fetal outcomes, breast cancer incidence, uterine function, ovarian function, diabetes and metabolic syndrome, bone density, and effects on women and neonatal thyroid hormones.</td>
</tr>
<tr>
<td>Shanghai Women's Health Study (SWHS)</td>
<td>Vanderbilt University (Wei Zheng)</td>
<td>NCI</td>
<td>74,942 Chinese women who were between ages 40 to 70 years at enrollment (1997-2000) and lived in urban Shanghai.</td>
<td>1997-2000</td>
<td>Measurements include surveys and biological samples (from 87.5% of participants).</td>
<td>Outcomes include breast and other cancers.</td>
</tr>
<tr>
<td>Study name</td>
<td>Institution (PI)</td>
<td>Funder(s)</td>
<td>Study population</td>
<td>Study period</td>
<td>Measurements</td>
<td>Health outcomes</td>
</tr>
<tr>
<td>------------------------------------------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>-----------</td>
<td>----------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Singapore Chinese Health Study</td>
<td>University of Minnesota (Jian-Min Yuan), National University of Singapore (Woon-Puay Koh), NIEHS (Stephanie J. London)</td>
<td>NCI</td>
<td>63,257 men and women, age 45–74, who were permanent residents or citizens of Singapore and who resided in government-built housing estates.</td>
<td>Ongoing research: 1993-present</td>
<td>Measurements include baseline survey, food frequency survey, demographics, current physical activity, reproductive history (women only), occupational exposure and medical history; and respiratory questionnaires; blood samples or buccal cell and spot urine samples (32,000); and blood, buccal, and urine samples from all incident cases of female breast and colorectal cancers beginning in April 1994.</td>
<td>Outcomes include respiratory effects and breast and other cancers.</td>
</tr>
<tr>
<td>Sister Study: Environmental and Genetic Risk Factors for Breast Cancer</td>
<td>NIEHS (Dale Sandler, Clarice Weinberg)</td>
<td>NIEHS, National Center on Minority Health and Health Disparities</td>
<td>50,000 women age 35 to 74 who have never been diagnosed with breast cancer but who have a biological sister who has been diagnosed with breast cancer.</td>
<td>Ongoing research: 2003-present</td>
<td>Measurements include baseline questionnaire data, fasting blood, first morning urine, household dust samples and toenail samples. Follow up includes health status questionnaire surveys (annual) and health, lifestyle and exposures surveys (every two to three years).</td>
<td>Outcomes include breast and other cancers, osteoporosis, CVD, diabetes, and/or autoimmune diseases.</td>
</tr>
<tr>
<td>Southern Community Cohort Study</td>
<td>Vanderbilt University (William Blot), Meharry Medical College, and IEL</td>
<td>NCI</td>
<td>86,000 residents, age 40 to 79, approximately two-thirds African American, of 12 southeastern US states.</td>
<td>Ongoing research: 2001-present</td>
<td>Measurements include baseline survey, blood samples, buccal samples and/or urine sample.</td>
<td>Outcomes include breast and other cancers and other common and chronic diseases.</td>
</tr>
<tr>
<td>Strong Heart Study</td>
<td>University of Oklahoma Health Sciences Center</td>
<td>NHLBI</td>
<td>4,500 American Indians from 13 tribes and communities in three geographic areas (AZ, OK, SD/ND).</td>
<td>Phase I (1989–1991); Phase II (1993–1995); Phase III (1998–1999); Phase IV (90 more families); Phase V (additional families, ongoing)</td>
<td>Measurements include clinical examinations during each phase including blood samples, urine samples, EKGs, and blood pressure measurements.</td>
<td>Outcomes include CVD.</td>
</tr>
<tr>
<td>Swedish Mammography Cohort (SMC)</td>
<td>National Institute of Environmental Medicine (Alicja Wolk)</td>
<td>National Institute of Environmental Medicine</td>
<td>Over 60,000 women living in two counties in central Sweden born between 1914 and 1948.</td>
<td>Ongoing research: 1987-present</td>
<td>Measurements include self-administered questionnaires, food consumption information, blood (subgroup), urine (subgroup), saliva (subgroup), and adipose tissue (subgroup).</td>
<td>Outcomes include chronic diseases, including breast and other cancers.</td>
</tr>
<tr>
<td>Women Physicians' Health Study</td>
<td>Emory University School of Medicine (Erica Frank)</td>
<td>Varied sources, including American Heart Association and CDC</td>
<td>4,501 female physicians (stratified sampling for original 10,000 selected), ages 30 to 70.</td>
<td>1993-1994</td>
<td>Measurements include questionnaires.</td>
<td>Outcomes include health measures and health-related activities, as well as demographics and professional characteristics of US female physicians.</td>
</tr>
<tr>
<td>Women's Health Initiative Study (WHI)</td>
<td>WHI (Staff, Ross Prentice)</td>
<td>NIH</td>
<td>161,808 generally healthy postmenopausal women ages 50–79 (68,132 clinical and 93,676 observational). 115,400 of these women are included in an extension study.</td>
<td>1991-2006; Extension Study until 2015</td>
<td>Measurements include a Randomized Clinical Trial (focusing on hormone therapy, diet, calcium/vitamin D), an Observational Study, a Community Prevention Study, clinical exams, blood samples, urine samples, and interviews.</td>
<td>Outcomes include CVD, breast and other cancers, and osteoporosis.</td>
</tr>
<tr>
<td>Study name</td>
<td>Institution (PI)</td>
<td>Funder(s)</td>
<td>Study population</td>
<td>Study period</td>
<td>Measurements</td>
<td>Health outcomes</td>
</tr>
<tr>
<td>------------</td>
<td>-----------------</td>
<td>-----------</td>
<td>------------------</td>
<td>--------------</td>
<td>--------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Women’s Lifestyle and Health</td>
<td>Department of Medical Epidemiology and Biostatistics, Tromso University, Norway (Elisabete Weiderpass Vainio)</td>
<td>Swedish Cancer Society</td>
<td>50,000 Swedish women age 30 to 49.</td>
<td>1991-1992, 2003-2004</td>
<td>Measurements include questionnaire on lifestyle factors.</td>
<td>Outcomes include cancer, CVD and other chronic diseases in young women.</td>
</tr>
<tr>
<td>Health, Eating, Activity, and Lifestyle Study (HEAL)</td>
<td>NCI (Rachel Ballard-Barbash), Fred Hutchinson Cancer Research Center (Anne McTiernan), City of Hope National Medical Center (Leslie Bernstein), New Mexico Tumor Registry (Charles Wiggins)</td>
<td>NCI</td>
<td>~1200 women with early-stage breast cancer recruited from Seattle area, New Mexico, and Southern California.</td>
<td>Ongoing research: 1996-present</td>
<td>Measurements include anthropometric measurements, hormone measurements, vitamin D, and genetic information (blood), mammographic density, and questionnaire including diet, physical activity, quality of life.</td>
<td>Outcomes include breast cancer recurrence and survival.</td>
</tr>
<tr>
<td>Life After Cancer Epidemiology (LACE)</td>
<td>Kaiser Foundation Research Institute (Bette Caan)</td>
<td>NCI</td>
<td>2,321 early stage breast cancer survivors (diagnosed 1997-2000) in Northern California or Utah, age 18-70, who had completed treatment other than adjuvant hormonal therapy and were free of recurrence.</td>
<td>2000-2004</td>
<td>Baseline data collected approximately two years post diagnosis and 5-6 years post diagnosis including annual questionnaires on demographics, medical history, anthropometry, diet, supplements, physical activity and quality of life.</td>
<td>Outcomes include breast cancer recurrence and mortality and overall mortality.</td>
</tr>
<tr>
<td>Pathways Study</td>
<td>Kaiser Foundation Research Institute (Lawrence Kushi)</td>
<td>NCI, DOD, American Cancer Society</td>
<td>Over 2,200 women who were at least 21 years old at breast cancer diagnosis with primary invasive breast cancer of any stage and no prior history of any cancer.</td>
<td>Ongoing research: 2006-present (recruitment 2006-2010)</td>
<td>Measurements include extensive baseline interview, blood and saliva samples; body measurements, self reported lifestyle updates, treatments, and outcomes every 12 to 24 months.</td>
<td>Outcomes include breast cancer survival, breast cancer recurrence, and response to chemotherapy.</td>
</tr>
<tr>
<td>Women's Environment, Cancer, and Radiation Epidemiology (WECARE) Study</td>
<td>Memorial Sloan-Kettering Cancer Center (Jonine Bernstein) and others</td>
<td>NIEHS</td>
<td>2,100 women with bilateral (700) and unilateral (1,400) breast cancer who were diagnosed prior to age 55.</td>
<td>Ongoing research: 2000-present</td>
<td>Measurements include questionnaire and blood samples for DNA analysis.</td>
<td>Outcomes include second (contralateral) primary breast cancer, with a focus on gene (ATM, BRCA 1/2)-environment (radiation) interactions.</td>
</tr>
</tbody>
</table>
Table S3. Guide to breast cancer cohort studies (studies assessing pubertal development).

<table>
<thead>
<tr>
<th>Study name</th>
<th>Institution (PI)</th>
<th>Funder(s)</th>
<th>Study population</th>
<th>Study period</th>
<th>Measurements</th>
<th>Health outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Johns Hopkins Collaborative Perinatal Study (JHCPS)</td>
<td>Johns Hopkins (Janet Hardy and Sam Shapiro), NIEHS (Matthew Longnecker, PI of DDE and PCBs Study)</td>
<td>NIEHS</td>
<td>Subset of NCCP mothers delivering at Johns Hopkins University Hospital between 1960-1965, their children until age 8, and grandchildren evaluated in 1992-1994.</td>
<td>1960-1994</td>
<td>Measurements include maternal blood samples, extensive questionnaires, language, speech, and behavior testing at 36 months, observations (in delivery room, 4 months, and 7 years), pediatric neurological exam at 12 months, psychological profiles, physical growth, and vision testing.</td>
<td>Outcomes include birth defects and other health endpoints to age 8.</td>
</tr>
<tr>
<td>The Stockholm Children Allergy and Environmental Prospective Birth Cohort Study (BAMSE)</td>
<td>Karolinska Institutet, Stockholm County Council, Astrid Lindgren Children's Hospital, Sachs Children's Hospital</td>
<td>Stockholm County Council, Vårdal Asthma and Allergy Foundation, Swedish Research Council, EU MeDALL project.</td>
<td>4089 children and their parents born 1994-1996 in Stockholm, Sweden.</td>
<td>Ongoing research: 1994-present</td>
<td>Measurements include blood and urine samples as well as questionnaire and clinical data.</td>
<td>This study focuses on allergies and asthma, but measurements include pubertal timing (age at menarche, age at voice change, Tanner stage).</td>
</tr>
<tr>
<td>Center for the Health Assessment of Mothers and Children of Salinas (CHAMACOS)</td>
<td>UC Berkeley (Brenda Eskenazi)</td>
<td>Various</td>
<td>536 children born in 2000-2001 followed from birth; 300 children age 9 added in 2010-2011.</td>
<td>Ongoing research: 1998-present (funded through 2014)</td>
<td>Measurements include blood, urine, breastmilk, house dust, and deciduous teeth samples, as well as evaluations of breast development in girls age 9-12.</td>
<td>Outcomes include birth weight, neurodevelopmental endpoints, pubertal timing, hormone function, obesity, asthma, and immune function.</td>
</tr>
<tr>
<td>Children's Health and the Environment in the Faroes (CHEF)</td>
<td>Harvard School of Public Health (Philippe Grandjean), Danish Institute of Public Health Department of Environmental Medicine (same), Faroese Hospital System Department of Occupational Medicine and Public Health (Pal Weihe), University of Southern Denmark</td>
<td>Arctic Monitoring and Assessment Program, DANCE, Danish Council for Strategic Research, Danish Medical Research Council, European Commission's Research Programme, US EPA, NIEHS</td>
<td>Cohort 1: 1022 children born 1986-1989; Cohort 2: 182 children born 1994-1995; Cohort 3: 656 children born in 1997-2000; Cohort 4: 148 children born 2000-2001; Cohort 5: 475 children born 2007-2009. All cohorts comprised children in the Faroe Islands and their mothers.</td>
<td>Ongoing research: 1986-present</td>
<td>Measurements include cord blood samples, multiple blood and hair samples from children, blood, hair, breast milk, and urine samples from mothers, and urine, hair, and semen samples from fathers, as well as questionnaire and health data. Biological samples have been analyzed for biomarkers of many organic chemicals and metals.</td>
<td>Outcomes include effects on growth and development, especially on neurobehavioral, cardiovascular, endocrine, and immunological functions. Includes data on puberty timing (Tanner staging, age at voice change).</td>
</tr>
<tr>
<td>Danish National Birth Cohort (DNBC)</td>
<td>Danish Ministry of Health Statens Serum Institut</td>
<td>Danish National Research Foundation</td>
<td>~97,000 children born 1997-2002 in Denmark and their mothers.</td>
<td>Ongoing research: 1997-present</td>
<td>Measurements include maternal blood samples (during pregnancy), cord blood samples, and infant blood samples, as well as questionnaire and clinical data.</td>
<td>Outcomes include pubertal timing (age at menarche, age at voice change, Tanner stage), allergies, birth defects, childhood cancers, and other childhood health outcomes.</td>
</tr>
<tr>
<td>Study name</td>
<td>Institution [PI]</td>
<td>Funder(s)</td>
<td>Study population</td>
<td>Study period</td>
<td>Measurements</td>
<td>Health outcomes</td>
</tr>
<tr>
<td>----------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>-----------------------</td>
<td>-----------------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Duisburg Birth Cohort Study</td>
<td>Ruhr-Universität Bochum (Michael Wilhelm)</td>
<td>North Rhine-Westphalia State Agency for Nature, Environment, and Consumer Protection, Environmental Agency of the Federal Republic of Germany</td>
<td>234 children and their mothers in Duisburg, Germany.</td>
<td>Ongoing research: 2000-2011</td>
<td>Measurements include cord blood samples, blood and urine samples from mothers and children, and breast milk samples from mothers, as well as questionnaire and clinical data. Biological samples have been analyzed for some persistent organic pollutants, endocrine disruptors, and hormones.</td>
<td>Outcomes include measurements of child development, including pubertal timing and sex hormone levels.</td>
</tr>
<tr>
<td>Environmental and Genetic Determinants of Puberty</td>
<td>Breast Cancer and the Environment Research Program (BCEREP), Mt. Sinai School of Medicine (Mary Wolff), Kaiser Permanente (Lawrence Kushi), and Cincinnati Children's Hospital Medical Center (Frank Biro)</td>
<td>NIEHS, NCI</td>
<td>&gt;1200 girls from East Harlem, NY, SF Bay Area, and Cincinnati area; age 6-8 at first visit.</td>
<td>Ongoing research: 2003-present</td>
<td>Measurements include hormonal changes, obesity, diet, family history, psychosocial stressors, environmental exposures (measured with biomarkers and otherwise), and genetic polymorphisms.</td>
<td>Outcomes include breast stages, menarche, peak height velocity, adult height, and menstrual cyclicity.</td>
</tr>
<tr>
<td>German Infant Nutritional Intervention study – Plus influence of pollution and genetics on allergy development (GIINiplus)</td>
<td>Helmholtz Zentrum München - Institute of Epidemiology I (Joachim Heinrich), University of Munich (Sibylle Koletzko), Kinderklinik und Poliklinik, Technische Universität München (Carl P. Bauer), Marien-Hospital Wesel, Department of Pediatrics (Dietrich Berdel), Institut für Umweltmedizinische Forschung Düsseldorf (Barbara Hoffmann)</td>
<td>Federal Ministry of Education and Research, Germany, Helmholtz Zentrum München - Institute of Epidemiology I</td>
<td>5,991 healthy, full-term newborns with and without family history of allergy born in Munich and Wesel, Germany, 1995-1998 (3,317 at ten-year follow-up).</td>
<td>Ongoing research: 1995-present</td>
<td>Measurements include blood and urine samples from children, as well as questionnaire, anthropometric, and clinical data.</td>
<td>This study is focused on allergies, but outcomes include pubertal timing (age at menarche, Tanner stage at 15).</td>
</tr>
<tr>
<td>Environment and Childhood Project (Infancia y Medio Ambiente, or INMA)</td>
<td>CREAL (Jordi Sunyer)</td>
<td>Multiple Spanish public health agencies and foundations</td>
<td>3,768 children and their mothers in seven areas of Spain.</td>
<td>Ongoing research: 1997-present (varies by cohort)</td>
<td>Measurements include biomarkers measured in cord blood, placenta, hair, and urine samples from children, biomarkers measured in maternal blood and urine, and questionnaires on parental occupation, diet, and lifestyle.</td>
<td>Outcomes include pubertal timing (assessed in ~400 children, planned for ~2000 more), growth, development, and asthma related outcomes.</td>
</tr>
<tr>
<td>Lessons in Epidemiology and Genetics of Adult Cancer from Youth (LEGACY Girls Study)</td>
<td>Columbia University (Mary Beth Terry), Cancer Prevention Institute of California (Esther John), Fox Chase Cancer Center (Mary Daly), University of Utah (Sandra Buys), Samuel Lunenfeld Research Institute of Mount Sinai Hospital (Irene Andrulis)</td>
<td>NIH</td>
<td>900 girls age 6-13 (449 enrolled as of October 2012) and a parent or guardian followed for up to five years; half of the girls are daughters of women enrolled in the Breast Cancer Family Registry, half have no family history of breast cancer.</td>
<td>New research: enrollment began 2012, five years of follow-up planned</td>
<td>Measurements include biomarkers and epigenetics in blood, urine, and saliva, anthropomorphic measurements, and surveys.</td>
<td>Outcomes include pubertal and psychosocial development.</td>
</tr>
<tr>
<td>Study name</td>
<td>Institution (PI)</td>
<td>Funder(s)</td>
<td>Study population</td>
<td>Study period</td>
<td>Measurements</td>
<td>Health outcomes</td>
</tr>
<tr>
<td>---------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>---------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Influences of Life-style related factors on the Immune System and the development of Allergies in childhood – Plus the influence of traffic emissions and genetics (LISAplus)</td>
<td>Helmholtz Zentrum München - Institute of Epidemiology I (J. Heinrich)</td>
<td>Partly by Public Health Forschungsverbund Bayern (BMBF), IUF</td>
<td>1,467 newborns from Munich, 976 from Leipzig, 348 from Wesel, and 306 from Bad Honnef; enrolled 1997-1999.</td>
<td>Ongoing research: 1997-present</td>
<td>Measurements include cord blood and blood samples from children, dust and air samples, and questionnaire, anthropometric, and clinical data.</td>
<td>This study is focused on allergies, but outcomes include pubertal timing (age at menarche, Tanner stage at 15).</td>
</tr>
<tr>
<td>Multicentre Allergy Study (MAS)</td>
<td>Charité - University Medicine, Berlin (Ulrich Wahn), University Hospital Düsseldorf, St. Joseph's Hospital Freiberg, Johannes Gutenberg University Mainz, Technical University of Munich</td>
<td></td>
<td>1,314 newborns and parents enrolled in 1990 in Germany (Berlin, Munich, Freiburg, Mainz, Düsseldorf).</td>
<td>Ongoing research: 1990-present</td>
<td>Measurements include blood and urine samples, dust samples, and questionnaire and clinical data.</td>
<td>This study is focused on allergies, but outcomes include pubertal timing (age at menarche, Tanner stage).</td>
</tr>
<tr>
<td>Millennium Cohort Study, UK (MCS)</td>
<td>Institute of Education at University of London, Economic and Social Research Council (Heather Joshi)</td>
<td>UK Government (ESRC and others)</td>
<td>18,819 children and their families from across the UK.</td>
<td>Ongoing research: 2001-present; study team plans to follow cohort through adulthood</td>
<td>Measurements include surveys and basic tests to assess child's physical, cognitive, social, and emotional development.</td>
<td>Various health outcomes, early life dynamics.</td>
</tr>
<tr>
<td>National Children's Study</td>
<td>NIH (Steven Hirschfeld), NIEHS, CDC, US EPA</td>
<td>HHS, NIH, CDC, US EPA</td>
<td>Pregnant women and their partners and couples planning to become pregnant, and their children. Has a goal of studying 100,000 children and their parents from child's birth to age 21.</td>
<td>Ongoing research: 2007-present</td>
<td>Measurements include biospecimens from children and parents, indoor air, dust, soil, and drinking water samples, physical/clinical examinations, and behavioral observations.</td>
<td>Outcomes include general health and development.</td>
</tr>
<tr>
<td>New England NCPP (National Collaborative Perinatal Project) and follow-up New England Family Study</td>
<td>HMS, HSPH (Stephen Buka), Brown University</td>
<td>NIH and others</td>
<td>17,000 individuals from NCPP, followed from birth to age 40.</td>
<td>Ongoing research: 1959-present</td>
<td>Measurements include periodic physical and mental health assessments and a series of cognitive, behavioral and social tests.</td>
<td>Outcomes mainly include mental health disorders with developmental origins, as well as substance use, learning disabilities, attention-deficit/hyperactivity disorder (ADHD), and cardiovascular disease.</td>
</tr>
<tr>
<td>Prevention and Incidence of Asthma and Mite Allergy (PIAMA)</td>
<td>Utrecht University (Bert Brunkreft)</td>
<td>Asthma Foundation, ZONMW, MinVrom, RIVM++</td>
<td>&gt;4000 pregnant women enrolled, children followed until age 8.</td>
<td>Ongoing research: 1996-2013</td>
<td>Measurements include blood and saliva samples from children and both parents, breast milk samples from mothers, and questionnaire and clinical data.</td>
<td>This study is focused on allergies and asthma, but outcomes include pubertal timing (age at voice change, pubertal stage).</td>
</tr>
</tbody>
</table>
References


De Alwis GKH, Needham LL, Barr DB. 2007. Automated solid phase extraction and quantitative measurement of 2,3-dibromo-1-propanol in urine using gas chromatography-mass spectrometry. Arch Environ Contam Toxicol 53:134-139.


ECHA. 2013. Candidate list of substances of very high concern for authorization. Available: 

Eckert E, Drexler H, Goen T. 2010. Determination of six hydroxyalkyl mercapturic acids in 
human urine using hydrophilic interaction liquid chromatography with tandem mass 
spectrometry (HILIC-ESI-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci 
878:2506-2514.

acids as metabolites of alkylating substances in urine samples of German inhabitants. Int J 
Hyg Environ Health 214:196-204.

Eckert E, Leng G, Gries W, Goen T. 2012. A method for the simultaneous determination of 
mercapturic acids as biomarkers of exposure to 2-chloroprene and epichlorohydrin in human 

occupational exposure to 2-chloroprene. Arch Toxicol.

Review of pesticide urinary biomarker measurements from selected US EPA children's 


variations in serum ochratoxin A levels in healthy population living in some regions of 

Espinosa-Mansilla A, Acedo-Valenzuela MI, Munoz de la Pena A, Canada Canada F, Salinas 
Lopez F. 2002. Determination of antitubercular drugs in urine and pharmaceuticals by LC 
using a gradient flow combined with programmed diode array photometric detection. 

Available: http://eur- 
8 April 2014].


IARC. 1986a. 1,2-dichloropropane. IARC Monogr Eval Carcinog Risks Hum 41:131.
IARC. 1989c. 1,3-dinitropyrene. IARC Monogr Eval Carcinog Risks Hum 46:201-213.
IARC. 1989e. 1,8-dinitropyrene. IARC Monogr Eval Carcinog Risks Hum 46:231-246.
IARC. 1993a. IQ (2-amino-3-methylimidazo[4,5-f]quinoline). IARC Monogr Eval Carcinog
Risks Hum 56:165-195.
IARC. 1993c. 4,4'-Methylenebis(2-chloroaniline) (MOCA). IARC Monogr Eval Carcinog Risks
Hum 57:271-303.
IARC. 1993d. Magenta and CI Basic Red 9. IARC Monogr Eval Carcinog Risks Hum 57:215-
234.
IARC. 1996b. 2-Nitrotoluene, 3-nitrotoluene and 4-nitrotoluene. IARC Monogr Eval Carcinog
Risks Hum 65:409-435.
IARC. 1999c. 1,4-Dioxane. IARC Monogr Eval Carcinog Risks Hum 71 Pt 2:589-602.
IARC. 1999d. 1,2-Dibromo-3-chloropropane. IARC Monogr Eval Carcinog Risks Hum 71 Pt 2:
479-500.
IARC. 1999f. Ethylene dibromide (1,2-dibromoethane). IARC Monogr Eval Carcinog Risks
Hum 71 Pt 2:641-669.
IARC. 1999i. 1,2-Dichloroethane. IARC Monogr Eval Carcinog Risks Hum 71 Pt 2:501-529.
IARC. 2000c. 2,2-Bis(bromomethyl)propane-1,3-diol. IARC Monogr Eval Carcinog Risks Hum 77:455-468.


NTP. 1979. NTP Technical Series No. 146; bioassay of nithiazide for possible carcinogenicity 
CAS No. 139-94-6 National Cancer Institute Carcinogenesis Technical Report Series No. 
146 (Natl Toxicol Program Tech Rep Ser).
NTP. 2004. NTP technical report on the toxicity studies of malachite green chloride and 
leucomalachite green (CAS Nos. 569-64-2 and 129-73-7) administered in feed to F344/N 
[accessed 7 April 2014].
adducts as a marker of exposure to chemical substances, especially PRTR class I designated 
2014].
analysis of yohimbine and related compounds by high-performance liquid chromatography. 


Schettgen T, Heinrich K, Kraus T, Gube M. 2010. Determination of 2,5-toluylene diamin (2,5-TDA) and aromatic amines in urine after personal application of hair dyes: kinetics and doses. Arch Toxicol.


